metformin and sitagliptin phosphate

metformin has been researched along with sitagliptin phosphate in 356 studies

Research

Studies (356)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's36 (10.11)29.6817
2010's252 (70.79)24.3611
2020's68 (19.10)2.80

Authors

AuthorsStudies
Bergman, A; Herman, GA; Kipnes, M; Yi, B1
Charbonnel, B; Karasik, A; Liu, J; Meininger, G; Wu, M1
Brazg, R; Cobelli, C; Dalla Man, C; Stein, PP; Thomas, K; Xu, L1
Meininger, G; Nauck, MA; Sheng, D; Stein, PP; Terranella, L1
Drucker, D; Easley, C; Kirkpatrick, P1
Feinglos, MN; Goldstein, BJ; Johnson, J; Lunceford, JK; Williams-Herman, DE1
Eldor, R; Raz, I1
Fanurik, D; Hermansen, K; Khatami, H; Kipnes, M; Luo, E; Stein, P1
Whitehill, D1
Mirza, SA1
Gallwitz, B1
Ahrén, B3
Aschner, P; Davies, MJ; Karasik, A; Katzeff, H; Stein, PP1
Alba, M; Amatruda, JM; Chen, Y; Hussain, S; Kaufman, KD; Langdon, RB; Raz, I; Stein, PP; Wu, M1
Davies, MJ; Engel, SS; Loeys, T; Scott, R1
Nogid, A; Pham, DQ; Plakogiannis, R1
Alemao, E; Chen, J; Cook, J; Gouveia, M; Jameson, K; Krishnarajah, G; Nocea, G; Schwarz, B; Sintonen, H; Yin, D1
Charbonnel, B; Cobelli, C; Davies, MJ; Man, CD; Meninger, G; Stein, PP; Williams-Herman, D; Xu, L1
Campbell, RK; Neumiller, JJ; Reynolds, JK1
Feinglos, M; Green, J1
Amatruda, JM; Davies, MJ; Goldstein, BJ; Johnson, J; Kaufman, KD; Luo, E; Teng, R; Williams-Herman, D1
Arnold Chan, K; Dore, DD; Seeger, JD1
Butler, AE; Butler, PC; Cox, HI; Dry, S; Galasso, R; Gurlo, T; Matveyenko, AV; Moshtaghian, A1
Keating, N1
Matthaei, S1
Bischoff, A1
Henson, K; Hight, R; Welborn, D; Wyatt, S1
Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA1
Alexander, CM; Siler, SQ; Topp, BG; Waters, SB1
Aschner, P; Goldstein, BJ; Guo, H; Katzeff, HL; Kaufman, KD; Sunga, S; Williams-Herman, D1
Amatruda, JM; Andryuk, PJ; Cefalu, WT; Chen, Y; Engel, SS; Katz, L; Kaufman, KD; Ling, Y; Luo, E; Musser, B; Rosenstock, J; Vilsbøll, T; Yki-Järvinen, H1
Ban, K; Drucker, DJ; Henkelman, RM; Husain, M; Momen, MA; Sauvé, M; Zhou, YQ1
Meier, JJ; Menge, BA; Schmidt, WE1
Agostini, C; Albiero, M; Avogaro, A; Boscaro, E; de Kreutzenberg, S; Fadini, GP; Frison, V; Menegazzo, L; Tiengo, A1
Aaboe, K; Deacon, CF; Holst, JJ; Knop, FK; Krarup, T; Madsbad, S; Vilsbøll, T1
Freeman, JS1
Scheen, AJ; Van Gaal, LF2
Aguila, MB; Cardoso-de-Lemos, FS; de Carvalho, L; Gregório, BM; Mandarim-de-Lacerda, CA; Souza-Mello, V1
Amatruda, JM; Goldstein, BJ; Golm, G; Johnson, J; Kaufman, KD; Teng, R; Williams-Herman, D1
Bailey, T; Cuddihy, R; Davies, M; Filetti, S; Montanya, E; Nauck, M; Pratley, RE; Søndergaard, RE; Thomsen, AB1
Amatruda, JM; Davies, MJ; Kaufman, KD; Nauck, M; Seck, T; Sheng, D; Stein, PP; Sunga, S1
Bergenstal, RM; Macconell, L; Malloy, J; Malone, J; Porter, LE; Walsh, B; Wilhelm, K; Wysham, C; Yan, P1
Meier, JJ; Nauck, MA1
Scheen, AJ2
Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME5
Charpentier, G; Gause-Nilsson, I; Hellqvist, A; Ostgren, CJ; Scheen, AJ1
Ahn, SH; Bae, MA; Choi, MK; Jin, QR; Song, IS1
Opsteen, C; Qi, Y; Retnakaran, R; Vivero, E; Zinman, B1
Gottesdiener, KM; Gutierrez, M; Johnson-Levonas, AO; Liu, Q; Matthews, CZ; Migoya, EM; Miller, JL; Wagner, JA; Zheng, W1
Boulton, DW; Griffen, SC; Kasichayanula, S; LaCreta, FP; Li, T; Liu, X; Pfister, M; Shyu, WC; Zhang, W1
Arechavaleta, R; Chen, Y; Duran, L; Goldstein, BJ; Kaufman, KD; Krobot, KJ; O'Neill, EA; Seck, T; Williams-Herman, D1
Hollander, P; Liutkus, JF; Raslova, K; Råstam, J; Skjøth, TV1
Seyoum, B1
Cuddihy, R; Davies, M; Hammer, M; Pratley, R; Thomsen, AB1
Chwieduk, CM1
Choi, SE; Han, SJ; Jung, JG; Kang, Y; Kim, DJ; Kim, HJ; Lee, KW; Yi, SA1
Bailey, T; Cuddihy, R; Davies, M; Filetti, S; Garber, A; Hartvig, H; Montanya, E; Nauck, M; Pratley, R; Thomsen, AB1
Chen, M; Goldstein, BJ; Johnson-Levonas, AO; Kaufman, KD; Olansky, L; Reasner, C; Seck, TL; Terranella, L; Williams-Herman, DE1
Bergenstal, R; Malloy, J; Malone, J; Taylor, K; Walsh, B; Wysham, C; Yan, P1
Denn, M; Gallagher, RT; Peter, RM; Swales, JG1
Daniela, L; Ludvik, B1
Engel, SS; Goldstein, BJ; Golm, GT; Kaufman, KD; Seck, TL; Sisk, CM; Wang, H; Williams-Herman, DE1
Chen, M; Goldstein, BJ; Kaufman, KD; Mehta, A; Olansky, L; Reasner, C; Seck, TL; Terranella, L; Williams-Herman, DE1
Ayoub, BM; El-Bagary, RI; Elkady, EF1
Engel, SS; Goldstein, BJ; Kaufman, KD; Lee, MA; Pérez-Monteverde, A; Seck, T; Sisk, CM; Williams-Herman, DE; Xu, L1
Chubb, BD; Davies, MJ; Smith, IC; Valentine, WJ1
Jermendy, G2
Ahn, HY; An, JH; Cho, YM; Choi, SH; Jang, HC; Kang, SM; Khang, AR; Lee, Y; Lim, S; Park, KS; Shin, H; Yoon, JW1
Davies, MJ; Goldstein, BJ; Golm, GT; Johnson, J; Kaufman, KD; Teng, R; Williams-Herman, D; Xu, L1
Kubota, A; Maeda, H; Matsuba, I; Tanaka, Y; Terauchi, Y1
Engel, SS; Goldstein, BJ; Golm, GT; Hussain, S; Katz, L; Kaufman, KD; O'Neill, EA; Wainstein, J; Xu, L1
Aso, Y; Hara, K; Haruki, K; Inukai, T; Morita, K; Naruse, R; Ozeki, N; Shibazaki, M; Suetsugu, M; Takebayashi, K; Terasawa, T1
Boardman, MK; Chan, M; Cuddihy, RM; González, JG; Hanefeld, M; Kumar, A; Russell-Jones, D; Wolka, AM1
Briand, F; Burcelin, R; Sulpice, T; Thieblemont, Q1
Bachmann, OP; Chan, JY; Lüdemann, J; Oliveira, JH; Reed, VA; Violante, R; Yoon, KH; Yu, MB1
Nauck, MA1
Berman, S; Efrati, S; Golik, A; Hamad, RA; Koren, S; Peleg, RK; Shemesh-Bar, L; Tirosh, A; Vinker, S1
Capuano, G; Nicolle, LE; Usiskin, K; Ways, K1
Alba, M; Engel, SS; Goldstein, BJ; Guan, Y; Johnson-Levonas, AO; Kaufman, KD; Li, Z; Shentu, Y; Yang, W1
Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Franzetti, I; Maffioli, P; Querci, F; Romano, D1
Aschner, P; Chan, J; Dain, MP; Echtay, A; Fonseca, V; Owens, DR; Picard, S; Pilorget, V; Wang, E1
Diamant, M1
Barbieri, M; Marfella, R; Paolisso, G; Rizzo, MR1
Davies, MJ; Ferrante, SA; Goldstein, BJ; Kaufman, KD; Krobot, KJ; Meininger, GE; Seck, T; Williams-Herman, D1
Amatruda, JM; Aschner, P; Chen, Y; Dobs, AS; Duran, L; Ferreira, JC; Goldstein, BJ; Golm, GT; Hill, JS; Horton, ES; Kaufman, KD; Langdon, RB; Umpierrez, GE; Williams-Herman, DE1
Daskiran, M; Dickson, WM; Kozma, CM; Nigam, S; Paris, A; Virdi, NS1
Colette, C; Comenducci, A; Dejager, S; Monnier, L; Vallée, D1
Arafat, T; Idkaidek, N1
Gupta, R; Keshwani, P; Saxena, GN; Srivastava, S1
Colette, C; Dejager, S; Guerci, B; Huet, D; Monnier, L; Petit, C; Quéré, S; Raccah, D; Serusclat, P; Valensi, P1
Langer, J; Lee, WC; Palmer, JL; Samyshkin, Y1
Bailey, T; Davies, M; Filetti, S; Furber, S; Garber, AJ; Montanya, E; Nauck, MA; Pratley, RE; Thomsen, AB1
Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F2
Inazumi, T; Kimura, M; Komatsu, Y; Kondo, Y; Nakamura, A; Tajima, K; Takihata, M; Tamura, H; Terauchi, Y; Yamada, M; Yamazaki, S1
Chung, CH; Jang, HC; Kim, JA; Kim, SW; Lee, WY; Min, KW; Nam-Goong, IS; Rhee, EJ; Shivane, VK; Sosale, AR1
Bakris, GL; Flynn, C1
Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Franzetti, IG; Maffioli, P; Piccinni, MN; Querci, F2
Bartola, LD; Giampietro, C; Giampietro, O; Masoni, MC; Matteucci, E1
Arai, K; Hirao, K; Hirao, S; Hirao, T; Maeda, H; Sirabe, S; Yamamoto, R; Yamauchi, M1
Gavish, D; Gevrielov-Yusim, N; Goldenberg, I; Gottlieb, S; Leibovitz, E; Matetzky, S1
Hunt, B; Langer, J; Valentine, WJ1
Canovatchel, W; Fu, M; Gross, JL; Guarisco, M; Kawaguchi, M; Meininger, G; Rosenstock, J; Schernthaner, G; Yee, J1
Adams, J; Cersosimo, E; DeFronzo, RA; Garduno-Garcia, Jde J; Solis-Herrera, C; Triplitt, C1
Charbonnel, B; Davies, MJ; Engel, SS; Eymard, E; Prabhu, V; Steinberg, H; Thakkar, P; Xu, L1
Schütt, M; Steinhoff, J; Süfke, S1
Buse, JB; Kahn, SE; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Staten, M; Wexler, D1
Bruce, SS; Connolly, ES; Heyer, EJ; Mergeche, JL1
Aston-Mourney, K; Goldstein, LC; Hull, RL; Meier, DT; Samarasekera, T; Subramanian, SL; Zraika, S1
Moniri, NH; Ryan, GJ; Smiley, DD1
Huang, Q; Peng, Y; Wang, Y; Zhao, L1
Du, Q; Liang, YY; Wang, YJ; Wu, B; Yang, S; Zhao, YY1
Derosa, G; Maffioli, P1
Andersson, C; Mogensen, UM; Scheller, NM; Torp-Pedersen, C; Vaag, A1
Canovatchel, W; Davidson, J; Januszewicz, A; Lavalle-González, FJ; Meininger, G; Qiu, R; Tong, C1
Cho, JH; Kim, ES; Kim, HS; Lee, SH; Shin, JA; Son, HY; Yoon, KH1
Hardy, E; Jabbour, SA; Parikh, S; Sugg, J1
Arndt, E; Deacon, CF; Holst, JJ; Nauck, MA; Vardarli, I1
Berk, A; Broedl, UC; Ferrannini, E; Hach, T; Hantel, S; Pinnetti, S; Woerle, HJ1
Li, H; Lu, J; Zang, J1
Bethel, MA; Califf, RM; Green, JB; Holman, RR; Kaufman, KD; Paul, SK; Ring, A; Shapiro, DR1
Ares-Carrasco, S; Caro-Vadillo, A; Egido, J; Iborra, C; Lorenzo, O; Picatoste, B; Ramírez, E; Tuñón, J1
Fathy, A; Khashab, S; Shaheen, N; Soliman, AR; Soliman, MA1
Gahler, RJ; Grover, GJ; Koetzner, L; Lyon, MR; Reimer, RA; Wood, S1
Cunningham, C; Dey, M; Forest, T; Frederick, C; Holder, D; Prahalada, S; Smith, A; Yao, X1
Schnell, O1
Bailey, RA; Blonde, L; Damaraju, CV; Martin, SC; Meininger, GE; Rupnow, MF1
Arai, K; Hirao, K; Hirao, S; Hirao, T; Kumakura, A; Maeda, H; Shirabe, S; Yamamoto, R; Yamauchi, M1
Forst, T; Goldenberg, R; Guthrie, R; Meininger, G; Stein, P; Vijapurkar, U; Yee, J1
Ferrannini, E; Mari, A; Polidori, D1
Coric, J; Dizdarevic-Bostandzic, A; Djelilovic-Vranic, J; Izetbegovic, S; Karamehic, J; Macic-Dzankovic, A; Panjeta, M; Velija-Asimi, Z1
Borders-Hemphill, V; Hampp, C; Moeny, DG; Wysowski, DK1
Hegazy, SK1
Bound, MJ; Checklin, H; Deacon, CF; Horowitz, M; Jones, KL; Ma, J; Rayner, CK; Wu, T1
Apseloff, G; Atiee, G; Bush, MA; Collins, DA; Corsino, L; Feldman, PL; Gillmor, D; McMullen, SL; Morrow, L; Nunez, DJ1
Guerci, B; Milicevic, Z; Nauck, M; Skrivanek, Z; Umpierrez, GE; Weinstock, RS1
Ahrén, B; Cirkel, DT; Feinglos, MN; Johnson, SL; Perry, C; Stewart, M; Yang, F1
Persson, U; Steen Carlsson, K1
Ban, N; Kawana, H; Murano, T; Nagayama, D; Nagumo, A; Ohira, M; Saiki, A; Shirai, K; Tatsuno, I; Yamaguchi, T1
Aaboe, K; Akram, S; Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S1
Marchesini, G; Melchiorri, D; Montilla, S; Pani, L; Sammarco, A; Siviero, PD; Tomino, C; Trotta, MP1
Ametov, AS; Gusenbekova, DG1
Furukawa, A; Ishihara, H; Kosuda, M; Nakazaki, M; Otsuka, Y; Yamaguchi, S1
Carpenter, KH; Chisholm, DJ; Coster, AC; Greenfield, JR; Gribble, FM; Holst, JJ; Jones, GR; Samocha-Bonet, D1
Ekoé, JM; Kuritzky, L; Landó, LF; Mancillas-Adame, L; Umpierrez, G1
Andersen, H; Hiort, LC; Linjawi, S; Rao, P; Sari, R; Sothiratnam, R1
Baik, SH; Choi, SH; Chung, CH; Jin, SM; Kim, DM; Lee, HW; Lee, IK; Lee, MK; Min, KW; Park, IB; Park, JY; Park, KS; Park, SW; Song, KH; Yoon, KH1
Thompson, AM; Trujillo, JM1
Amin, NB; Jain, SM; Lee, DS; Nucci, G; Rusnak, JM; Wang, X1
Dong, Q; Engel, SS; Goldstein, BJ; Golm, GT; Johnson, JR; Katzeff, HL; Kaufman, KD; O'Neill, EA; Wang, H; Williams-Herman, D; Xu, L1
Aggarwal, N; Amin, NB; Calle, RA; Denney, WS; Le, V; Pall, D; Paragh, G; Riggs, M1
Guerci, B; Milicevic, Z; Nauck, MA; Skrivanek, Z; Umpierrez, G; Weinstock, RS1
Drzewoski, J; Kasznicki, J; Marczak, A; Rogalska, A; Sliwinska, A2
Blonde, L; Brodovicz, KG; Brudi, P; Engel, SS; Fan, CP; Hanna, B; Inzucchi, SE; Li, Z; Mavros, P; Qiu, Y; Radican, L; Rajpathak, S; Tang, J; Tunceli, K1
Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M1
Benard, N; Chanut-Vogel, C; Dallongeville, J; de Pouvourville, G; Eymard, E; Kempf, C; Moisan, C; Valensi, P1
Lotfy, HM; Mohamed, D; Mowaka, S1
Ahmad, I; Ahmed, I; Mukhopadhyay, A; Reddy, S; Thangam, S1
Ahrén, B; Cho, YM; Choi, SH; Jang, HC; Jung, KY; Kim, KM; Kim, YJ; Ku, EJ; Lim, S; Moon, JH; Park, KS1
Huang, X; Liu, Z; Rajpathak, S; Shankar, RR1
Högger, P; Scherf-Clavel, M1
Fukase, H; Harigai, M; Iida, S; Ikeda, S; Kasahara, N; Miyata, K; Ohba, Y; Saito, T; Takano, Y; Terao, K1
Federici, M; Kappel, BA; Marx, N1
Afzal, A; Ashraf, H; Bajwa, SZ; Haq, I; Hussain, T; Iqbal, N; Mujahid, A; Shehzad, K1
Fath, R1
D'Angelo, A; Derosa, G; Maffioli, P1
Balladares, N; Contreras, M; D'Marco, L; Iacobellis, G; Lima-Martínez, MM; Paoli, M; Rodney, M1
Brouwers, PJ; den Hertog, HM; Dippel, DW; Fonville, S; Koudstaal, PJ; Lingsma, HF; Mulder, LJ; Osei, E; Zandbergen, AA1
Brown, C; Chastain, LM; Maggu, GA; Vuylsteke, V1
Dungan, KM; Fahrbach, JL; Raz, I; Sealls, W; Skrivanek, Z1
Ferrario, MG; Lizán, L; Montagnoli, R; Ramírez de Arellano, A1
Alba, M; Cerdas, S; Chacon, Mdel P; Eliaschewitz, FG; Lavalle-González, FJ; Tong, C1
Engel, SS; Gantz, I; Goldstein, BJ; Golm, GT; Kaufman, KD; Moses, RG; O'neill, EA; Round, E; Shentu, Y1
Chen, C; Li, L; Li, M; Li, Y; Ou, M; Xu, X1
Tong, N; Zhang, L; Zhang, M; Zhang, Y1
García Díaz, E; Godoy, T; Guagnozzi, D; Gutiérrez, V; Larrañaga, Y; Maza, C; Mendoza, C; Perdomo, D; Taleb, G1
Geurin, MD1
Cao, J; Ji, M; Xia, L; Zou, D1
Bian, F; Bosch-Traberg, H; Geng, J; Li, Y; Liu, J; Liu, Y; Luo, Y; Lv, X; Mu, Y; Peng, Y; Sun, Y; Yang, J; Zang, L1
Ferenci, T; Simonyi, G1
Aggarwal, N; Alba, M; Cao, A; Fung, A; Pfeifer, M; Rodbard, HW; Seufert, J1
Engel, SS; Golm, GT; Han, P; Ji, L; Jou, YM; Kaufman, KD; Liu, J; O'Neill, EA; Shankar, RR; Wang, X; Zheng, S1
Chung, SC; Kim, IJ; Kim, SS; Kim, YI; Lee, KJ; Lee, SJ; Lee, YS; Park, JH1
Georgy, A; Liang, Z; Zhai, S; Zhi, J1
Baranov, O; Deacon, CF; Holst, JJ; Kahle, M; Nauck, MA2
Bailey, TS; Kaltoft, MS; Maislos, M; Rao, PV; Takács, R; Thomsen, AB; Tinahones, FJ; Tsoukas, GM1
Canovatchel, W; Davidson, JA; Jodon, H; Lavalle-González, FJ; Qiu, R; Schernthaner, G; Vijapurkar, U1
Cahen, DL; Diamant, M; Groen, AK; Hoekstra, T; Kramer, MH; Muskiet, MH; Nieuwdorp, M; Smits, MM; Tonneijck, L; van Raalte, DH1
Johansen, P; Neslusan, C; Sabapathy, S; Teschemaker, A; Willis, M; Yoong, K1
Anderson, R; Hayes, J; Stephens, JW1
Ba, J; Engel, SS; Han, P; Hanson, ME; Mo, Z; Pan, C; Shankar, RR; Wu, F; Xu, L; Yuan, G1
Sanyal, M; Shah, JV; Shah, PA; Shrivastav, PS1
Bloomgarden, ZT; Brodovicz, KG; Brudi, P; Chen, Y; Engel, SS; Fonseca, V; Liu, J; Mavros, P; Qiu, Y; Radican, L; Rajpathak, S; Tunceli, K1
Anzola, I; Duan, W; Hudson, M; Pasquel, FJ; Peng, L; Smiley, DD; Stefanovski, D; Umpierrez, GE; Vellanki, P1
Adler, A; Armstrong, PW; Bethel, MA; Buse, JB; Green, JB; Holman, RR; Josse, RG; Kaufman, KD; Majumdar, SR; Peterson, ED; Rodbard, HW; Tankova, T; Westerhout, CM; Zheng, Y1
Aoki, S; Atsumi, T; Furumoto, T; Inoue, A; Kurihara, Y; Manda, N; Miyoshi, H; Nomoto, H; Oba, K; Tsutsui, H1
Bao, Y; Engel, SS; Han, P; Hu, J; Jia, W; Ma, J; Peng, Y; Shankar, RR; Wu, F; Xu, L1
Arturi, F; Gallelli, L; Palleria, C; Ruffo, M; Serra, R; Succurro, E1
Torjesen, I1
Aggarwal, R; Jaggi, S; Juneja, D; Saraswat, V; Sehra, D; Sehra, S1
Amin, NB; Denham, DS; Denney, WS; Riggs, MR1
Demir, S; Sargin, M; Temizkan, S1
Alegria, V; Andres, I; Fuertes, L; Gimeno, I; Lopez, J; Macias, E; Perez, A; Perez, Y; Ramírez-Bellver, JL; Requena, L1
Abd-Elaziz, LF; Aboul-Fotouh, S; El-Kharashi, OA; Magdy, YM; Nabih, ES; Shaker, SM1
Engel, SS; Fujita, KP; Kaufman, KD; Liu, X; Ma, J; Ning, G; O'Neill, EA; Shankar, RR; Wang, W; Wu, F; Xu, L; Zheng, S1
Chung, CH; Han, KA; Hong, SM; Hwang, DM; Lee, CB; Mok, JO; Park, CY; Park, KS; Park, SW; Yoon, KH1
Cho, JH; Hur, GC; Jang, YH; Jung, CH; Kim, JH; Kim, SH; Lee, BW; Lee, SH; Lee, WJ; Park, CY; Park, SE; Suh, S1
Andryuk, PJ; Engel, SS; Gantz, I; Goldenberg, R; Kaufman, KD; Lai, E; O'Neill, EA; Suryawanshi, S; Wang, YN1
Branum, A; Malik, M; Puppala, VK; Signorelli, K; Suboc, TM; Tanner, MJ; Tyagi, S; Wang, J; Widlansky, ME; Ying, R1
Atif, MA; Ghafoor, MB; Hussain, M1
Miyagi, K; Mutoh, A; Takasu, N; Yabiku, K1
Gadde, KM; Hardy, E; Iqbal, N; Öhman, P; Vetter, ML1
Cao, C; Marcinak, JF; Peng, XV; Raanan, MG1
Jung, K; Shah, N; Vashisht, R1
Bi, Y; Engel, SS; Ji, L; Ji, Q; Jia, W; Lu, J; Mao, A; Mu, Y; Ran, X; Weng, J; Xu, W; Yang, W; Yao, B; Zeng, L; Zhao, B; Zhao, J; Zhou, Z; Zhu, D1
Anglin, G; Barkin, JS; Frossard, JL; Harper, KD; Hensley, IE; Milicevic, Z; Nauck, MA1
Bilz, S; Brändle, M; Fournier, JY; Quarella, M; Walser, D1
Lingvay, I1
Chen, W; Liu, X; Mei, T; Ye, S1
El-Zaher, AA; Elkady, EF; Elwy, HM; Saleh, MAEM1
Chmelik, M; Harreiter, J; Kautzky-Willer, A; Kosi-Trebotic, L; Thomas, A; Trattnig, S1
Li, H; Li, S; Wang, R; Zhang, JP1
Amorin, G; Dagogo-Jack, S; Eldor, R; Engel, SS; Golm, G; Hille, D; Huyck, S; Johnson, J; Lauring, B; Liao, Y; Liu, J; Mancuso, JP; Terra, SG1
Jiang, D; Li, M; Wang, Y; Yang, Y; Ying, M; Zhao, R1
Beckley, N; Nazareth, I; Petersen, I; Sharma, M1
Eldor, R; Engel, SS; Golm, G; Huyck, SB; Johnson, J; Lauring, B; Mancuso, JP; Pratley, RE; Qiu, Y; Raji, A; Sunga, S; Terra, SG1
Chung, CH; Jang, HC; Jung, CH; Lee, WY; Min, KW; Nam-Goong, IS; Rhee, EJ; Shivane, VK; Sosale, AR1
Markham, A1
Elkind-Hirsch, KE; Gutowski, HC; Paterson, MS; Shaler, D1
Ahrén, B; Farngren, J; Persson, M1
Ejima, T; Nagao, T; Wakisaka, M; Yoshizumi, H1
Alvey, C; Cutler, DL; Dawra, VK; Hickman, A; Krishna, R; Liang, Y; Sahasrabudhe, V; Saur, D; Shi, H; Terra, SG; Zhou, S1
Dalal, K; Ganguly, B; Gor, A1
Garcia de Lucas, MD; Gómez Huelgas, R; Olalla Sierra, J; Pérez Belmonte, LM; Suárez Tembra, M1
Baik, S; Cha, BS; Chon, S; Chung, CH; Han, KA; Jung, CH; Kim, DS; Lee, IK; Lee, KW; Lee, MK; Lim, S; Park, KS; Park, S; Sakatani, T; Yoon, KH1
Anzola, I; Dungan, KM; Gianchandani, RY; Gomez, P; Hodish, I; Iyengar, J; Lathkar-Pradhan, S; Pasquel, FJ; Rubin, DJ; Umpierrez, GE; Vellanki, P; Wang, H1
Fajtova, V1
Abbas, NAT; El Salem, A1
Al-Amin, MA; Al-Damry, NT; Al-Rasheed, NM; Atteya, M; Attia, HA; Dizmiri, N; Mohamad, RA1
Frias, JP; McPheeters, JT; Parker, ED; Wittbrodt, ET1
Chen, G; Engel, SS; Lin, J; Liu, S; O'Neill, EA; Shankar, RR; Tu, Y; Yu, M; Zhang, R; Zhang, Y1
Deng, H; Dou, J; Hong, T; Huang, Q; Kang, Z; Kuang, H; Li, Y; Luo, S; Qin, G; Shan, Z; Tan, Y; Weng, J; Xiao, X; Xu, F; Xu, W; Yan, J; Yang, W; Yang, X; Yao, B; Yuan, H; Zeng, L1
Choi, KM; Jang, HC; Kang, ES; Kim, DJ; Kim, ES; Kim, NH; Kim, SJ; Kim, SR; Kim, Y; Lee, MK; Oh, T; You, J1
Lansang, MC1
Darmiento, C; Duran-García, S; Engel, SS; Gantz, I; Golm, GT; Kaufman, KD; Lam, RLH; O'Neill, EA; Roussel, R; Shah, S; Shankar, RR; Zhang, Y1
Bass, A; Dawra, VK; Fediuk, DJ; Hickman, A; Krishna, R; Liang, Y; Matschke, K; Sahasrabudhe, V; Shi, H; Terra, SG; Zhou, S1
Del Prato, S; Garcia-Sanchez, R; Handelsman, Y; Iqbal, N; Johnsson, E; Kurlyandskaya, R; Mathieu, C; Rosenstock, J1
Bachmann, HS; Besser, M; Koester, V; Severing, AL; Stuermer, EK; Terberger, N1
Afarideh, M; Alemi, H; Asadi Komeleh, S; Esteghamati, A; Esteghamati, S; Khaloo, P; Mansournia, MA; Mohammadi, A; Nakhjavani, M; Yadegar, A1
Bilir, SP; Davies, G; Gonzalez, C; Kowal, S; Pawaskar, M; Rajpathak, S1
Amorin, G; Crutchlow, MF; Engel, SS; Frias, JP; Iredale, C; Kaufman, KD; Lam, RLH; Makimura, H; Ntabadde, C; O'Neill, EA; Zimmer, Z1
Frias, JP1
Weng, J1
Upala, S1
Allison, D; Birkenfeld, AL; Blicher, TM; Davies, M; Deenadayalan, S; Jacobsen, JB; Rosenstock, J; Serusclat, P; Violante, R; Watada, H1
Hirsch, IB1
Aguirre, C; Arion, A; Ayala, I; Cárceles-Rodríguez, CM; Fernández-Varón, E; Martín-Gimenez, T; Rodríguez, MJ1
Kuhad, A; Razdan, K; Sharma, R1
Baba, Y; Hashimoto, N; Hattori, A; Horikoshi, T; Ide, K; Ide, S; Ishibashi, R; Ishikawa, K; Ishikawa, T; Kitamoto, T; Kobayashi, A; Kobayashi, K; Koshizaka, M; Maezawa, Y; Nagashima, K; Nakamura, S; Newby, LK; Ogino, J; Ohara, E; Onishi, S; Sakamoto, K; Sato, Y; Shimada, F; Shimofusa, R; Shoji, M; Takahashi, S; Takemoto, M; Tokuyama, H; Uchida, D; Yamaga, M; Yokoh, H; Yokote, K2
Cusi, K1
Bai, R; Du, J; Liu, D; Shi, C; Wang, H; Wang, Y; Zhang, R; Zhang, X1
Catena, G; D'Angelo, A; Derosa, G; Maffioli, P; Romano, D; Tritto, I1
Freeman, MW; Halvorsen, YD; Lock, JP; Zhou, W; Zhu, F1
Fuhr, U; Kinzig, M; Scherf-Clavel, O; Sörgel, F; Stoffel, MS1
Shang, J; Wang, Q; Zhang, Y; Zhou, W1
Lipscombe, LL1
Ben Nasr, M; Fiorina, P; Loretelli, C; Malvandi, AM; Zuccotti, GV1
Taneja, V1
Weng, J; Yan, J; Yang, D1
Campbell, SA; Light, PE; Simpson, SH1
Feng, R; Liu, W; Ma, J; Qian, C; Wang, Z; Yang, M; Zhang, M1
Almajaan, A; Andrews, GP; Gilvary, GC; Healy, AM; Jones, DS; Kelleher, JF; Li, S; Loys, ZS; Madi, AM; Tian, YW1
Jackuliak, P; Killinger, Z; Kužma, M; Payer, J1
Davies, MJ; Kim, KM; Ku, EJ; Lee, JE; Lee, JH; Lee, SY; Lim, S1
Moradi, M; Mortazavinik, S; Sohrabi, MR1
Cui, L; Hao, Z; Li, G; Sun, Y; Yan, D1
Feng, R; Liu, W; Ma, J; Qian, C; Rayner, CK; Yang, M; Yue, J; Zhang, M1
Bolze, S; Fouqueray, P; Perrimond-Dauchy, S1
Chen, G; Engel, SS; Ji, Q; Liu, S; Liu, X; Wang, L; Weng, J; Xing, Y; Xu, W; Yao, B; Zeng, L; Zhang, R; Zhang, Y1
Cha, BS; Choi, DS; Choi, KM; Chun, SW; Kim, DM; Kim, KJ; Kim, MK; Kim, SG; Lee, HW; Lim, S; Mok, JO; Park, KS; Seo, JA; Shon, HS; Yoon, KH1
Daneshjou, D; Shariat Zadeh, SMA; Soleimani Mehranjani, M; Zadeh Modarres, S1
Baggio, LL; Cao, X; Drucker, DJ; Holman, RR; Koehler, JA; Lokhnygina, Y; Stevens, SR; Varin, EM1
Cortese, V; Davies, MJ; Jacquot, E; Khunti, K; Seidu, S; Tyrer, F; Zaccardi, F1
Ferrannini, E; Katsiki, N1
Hansen, HS; Jessen, JB; Johannsen, ML; Munkboel, CH; Styrishave, B1
Daneshjou, D; Shariatzadeh, MA; Soleimani Mehranjani, M; Zadeh Modarres, S1
Alsumali, A; Briggs, A; Davies, G; Kowal, S; Lautsch, D; Li, Q; Rajpathak, S; Wehler, E1
Fujihara, K; Furukawa, K; H Yamada, M; Hatta, M; Ikarashi, T; Iwanaga, M; Katagiri, T; Kitazawa, M; Matsunaga, S; Sone, H; Suzuki, H; Tanaka, S; Yamada, T; Yamamoto, M1
Belzer, C; Cahen, DL; Davids, M; de Vos, WM; Fluitman, KS; Groen, AK; Herrema, H; Kramer, MHH; Nieuwdorp, M; Smits, MM; van Raalte, DH1
Engel, SS; Kadowaki, T; Kaku, K; Kaufman, KD; O'Neill, EA; Okamoto, T; Sato, A; Seino, Y; Shirakawa, M2
Nunes, A; Rojas, G1
Fu, BY; Wang, XJ1
Ismail, K; Moulton, CD; Pickup, JC; Rokakis, AS; Stahl, D; Young, AH1
Bamehr, H; Janani, L; Mirzabeigi, P; Montazeri, H; Tanha, K; Tarighi, P1
Abdul-Azim Mohammad, M; Elkady, EF; Fouad, MA; Salem, WA1
Cai, ZJ; Chen, T; Li, N; Lin, WQ; Liu, MB; Zheng, B1
Brouwers, PJAM; den Hertog, H; Dippel, DWJ; Koudstaal, P; Lingsma, H; Mulder, LJMM; Osei, E; Zandbergen, A1
Barbosa, AM; Dos Santos, C; Ferreira, FBD; Figueiredo, BS; Ortsäter, H; Rafacho, A1
Chien, KL; Wang, J; Wu, HY1
Braga, M; Gerstein, HC; Goldenberg, R; Gupta, N; Hall, S; Hramiak, I; Liu, YY; McInnes, N; Otto, R; Rabasa-Lhoret, R; Sherifali, D; Sigal, RJ; Smith, A; Sultan, F; Woo, V1
Deeb, A; Engel, SS; Garcia, R; Golm, GT; Jalaludin, MY; Kaufman, KD; Lam, RLH; Newfield, RS; Rosario, CA; Saha, CK; Samoilova, Y; Scherer, LW; Shankar, RR; Shehadeh, N; Zeitler, P; Zhang, Y; Zilli, M2
Cao, Y; Fu, Y; Gao, XM; Li, T; Liu, SQ; Liu, X; Liu, YP; Ma, YP; Shi, P; Sun, FF1
Chen, FW; Hou, KJ; Khan, BA; Wu, Z; Wu, ZZ; Zhang, S1
Ferrannini, E; Lim, S; Shin, Y; Sohn, M1
Abdallah, FF; Abdelaleem, EA; Emam, AA; Magdy, F1
Daneshjou, D; Mehranjani, MS; Mofarahe, ZS; Shariatzadeh, SMA; Zadehmodarres, S1
Aftab, T; Ali, I; Bedar, R; Hanif, S; Iqbal, J; Murtaza, SH; Raza, A; Shakir, R; Syed, MA1
Cui, W; Kong, L; Yang, X; Zhou, ST1
Arapieva, AM; Bobrik, AG; Bobrik, DV; Khamitova, AD; Kuznetsov, KO; Mahmutova, EI; Nagaev, IR; Saetova, AA1
Cheng, MZ; Gao, Y; Liu, L; Zhan, ZT; Zhou, WJ1
Feng, Y; Ge, Y; He, Y; Hou, L; Huo, M; Ji, Y; Li, H; Liu, X; Liu, Y; Luo, Q; Qian, F; Wang, J; Wei, Y; Wu, S; Wu, Y; Xue, F; Yu, Y1
Qu, S; Sun, H; Wang, X; You, H; Zhao, B1
Balasubramanyam, A; Burch, HB; Buse, JB; Butera, NM; Cohen, RM; Crandall, JP; Kahn, SE; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Rasouli, N; Tiktin, M; Wexler, DJ; Younes, N1
Bebu, I; Burch, HB; Buse, JB; Cherrington, AL; Fortmann, SP; Green, JB; Kahn, SE; Kirkman, MS; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Phillips, LS; Pop-Busui, R; Steffes, M; Tiktin, M; Tripputi, M; Wexler, DJ; Younes, N1
Crown, W; Deng, Y; Dhruva, SS; Gandotra, C; Herrin, J; Lyon, TD; McCoy, RG; Noseworthy, P; Polley, EC; Quinto, K; Ross, JS; Shah, ND; Wallach, JD; Yao, X1
Aamir, AH; Ahmed, I; Asghar, A; Ghaffar, T; Ishtiaq, O; Khan, S; Kumar, S; Masood, F; Raja, UY; Randhawa, FA; Raza, A; Rehman, T; Sherin, A; Wahab, MU1
Cauchon, M; Lanthier, L; Mutchmore, A; Plourde, MÉ1
Ahmed, A; Ali, M; Fazal-Ur-Rehman, S; Wasim, AA1
Angwin, CD; Britten, N; Hattersley, AT; Holman, R; Jones, AG; Pearson, ER; Sattar, N; Shepherd, MH; Shields, BM1
Athar, M; Garg, A; Khan, MA; Kohli, S; Parveen, R; Vohora, D1
Ahn, KJ; Choi, KM; Chung, CH; Jang, HC; Kim, DM; Kim, SG; Kwon, SK; Lee, SH; Lee, YH; Park, HK; Park, KS; Son, HS; Song, KH; Won, KC; Yu, JM1
Brown, K; Donato, AA1
Kang, SM; Lim, S; Sohn, M; Yun, HM1
Abdelrahman, KS; Abu-Hassan, AA; Alsaggaf, WT; El Hamd, MA; Soltan, OM1
Fuhr, U; Gründemann, D; Gu, Y; Hagos, Y; Hsin, CH; Jedlitschky, G; Kuehne, A1
Bebu, I; de Boer, IH; Ghosh, A; Inzucchi, SE; Ismail-Beigi, F; McGill, JB; Mudaliar, S; Schade, D; Steffes, MW; Tamborlane, WV; Tan, MH; Wexler, DJ; Younes, N1
Arya, VV; Giri, R; Gofne, SK; Gupta, SK; Joglekar, SJ; Karnawat, SR; Kumar, SR; Kurmi, P; Lakhwani, LK; Mehta, SC; Mishra, A; Mohan, B; Murthy, LS; Patel, PM; Rajurkar, MN; Sahay, RK; Sawardekar, VM; Shembalkar, JV; Sonawane, AR; Soni, PN1
Jayabal, D; Jayanthi, S; Shimu, MSS; Thirumalaisamy, R1
Ahmed, M; Butt, TS; Ganesan, S; Khatri, M; Kumar, S; Madhurita, F; Nageeta, F; Patel, T; Sohail, R; Varrassi, G; Zafar, M; Zafar, W; Zaman, MU1
Atonal-Flores, B; Barranco-Juarez, A; León-Vázquez, ML1
Hong, JH; Lim, S; Moon, JS; Seong, K1
Ali, AM; Mostafa, MAA; Rabea, H; Salem, HF; Zakaraia, HG1
Ioji, T; Ishihara, H; Kosakai, Y; Watanabe, K; Yamaguchi, S1
Ahmed, S; Ali, SM; Baqar Abidi, SH; Kamal, J; Kanpurwala, MA; Khan, A; Khan, M; Khan, RA; Lohano, V; Mahmudi, NF; Saghir, M; Uddin, F1
Doubský, J; Douša, M; Gibala, P; Jireš, J; Kalášek, S; Kluk, A; Mervart, D; Pěček, D; Řezanka, P; Veseli, A1

Reviews

39 review(s) available for metformin and sitagliptin phosphate

ArticleYear
DPP-4 inhibitors.
    Best practice & research. Clinical endocrinology & metabolism, 2007, Volume: 21, Issue:4

    Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin

2007
Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.
    Current medical research and opinion, 2008, Volume: 24, Issue:2

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles

2008
Sitagliptin: a novel agent for the management of type 2 diabetes mellitus.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Mar-15, Volume: 65, Issue:6

    Topics: Diabetes Mellitus, Type 2; Digoxin; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiazolidinediones; Triazoles

2008
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
    Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:12

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2008
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
    Vascular health and risk management, 2008, Volume: 4, Issue:2

    Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin

2008
Janumet: a combination product suitable for use in patients with Type 2 diabetes.
    Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Interactions; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Triazoles

2008
New combination treatments in the management of diabetes: focus on sitagliptin-metformin.
    Vascular health and risk management, 2008, Volume: 4, Issue:4

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Patient Satisfaction; Pyrazines; Quality of Life; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2008
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
    Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:4

    Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Metformin; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sensitivity and Specificity; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin

2009
[GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus].
    Medizinische Klinik (Munich, Germany : 1983), 2010, Volume: 105, Issue:3

    Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Pyrazines; Risk Factors; Satiety Response; Sitagliptin Phosphate; Triazoles; Weight Loss

2010
Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.
    Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:10

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles

2010
Sitagliptin and metformin--novel combination therapy.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:4

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles

2011
Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.
    Drugs, 2011, Feb-12, Volume: 71, Issue:3

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles

2011
[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
    Orvosi hetilap, 2011, Sep-11, Volume: 152, Issue:37

    Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Metformin; Nitriles; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Tablets; Treatment Outcome; Triazoles; Vildagliptin

2011
[Incretin-based therapy for treating patients with type 2 diabetes].
    Orvosi hetilap, 2011, Nov-27, Volume: 152, Issue:48

    Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin

2011
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
    Diabetes & metabolism, 2012, Volume: 38, Issue:2

    Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain

2012
The design of the liraglutide clinical trial programme.
    Diabetes, obesity & metabolism, 2012, Volume: 14 Suppl 2

    Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms

2012
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
    Nature reviews. Nephrology, 2013, Volume: 9, Issue:3

    Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin

2013
Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, Jul-01, Volume: 70, Issue:13

    Topics: Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Evidence-Based Medicine; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms

2013
Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis.
    Current medical research and opinion, 2013, Volume: 29, Issue:11

    Topics: Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles

2013
Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Biomarkers; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Metformin; Outcome Assessment, Health Care; Pioglitazone; Proinsulin; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles

2013
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and sitagliptin].
    Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139 Suppl 2

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiophenes; Triazoles; Young Adult

2014
Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.
    Postgraduate medicine, 2014, Volume: 126, Issue:6

    Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms

2014
Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
    The Annals of pharmacotherapy, 2015, Volume: 49, Issue:3

    Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms

2015
Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2015, Volume: 25, Issue:8

    Topics: Adamantane; Administration, Oral; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Risk Factors; Sitagliptin Phosphate; Thiazolidinediones

2015
Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes.
    Drugs in R&D, 2015, Volume: 15, Issue:3

    Topics: Apoptosis; Blood Glucose; Diabetes Mellitus, Type 2; Gluconeogenesis; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Metformin; Sitagliptin Phosphate; Triazines

2015
Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:1

    Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Exenatide; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Liraglutide; Male; Metformin; Middle Aged; Peptides; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Venoms; Weight Gain

2016
Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review.
    Scientific reports, 2016, Jan-08, Volume: 6

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Insulin Glargine; Liraglutide; Metformin; Patient Safety; Peptides; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Venoms

2016
Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Animals; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Metformin; Sitagliptin Phosphate

2016
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:7

    Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Piperidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uracil

2017
Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
    Medicine, 2017, Volume: 96, Issue:39

    Topics: Diabetes Mellitus, Type 2; Drug Monitoring; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Outcome

2017
Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis.
    BMJ open, 2017, Oct-30, Volume: 7, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Outcome Assessment, Health Care; Sitagliptin Phosphate; Sulfonylurea Compounds; Weight Loss; Young Adult

2017
Ertugliflozin: First Global Approval.
    Drugs, 2018, Volume: 78, Issue:4

    Topics: Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; United States; United States Food and Drug Administration

2018
Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with premixed insulin.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:2

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Incidence; Insulin; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Sitagliptin Phosphate; Treatment Outcome

2019
Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes.
    Expert review of endocrinology & metabolism, 2019, Volume: 14, Issue:2

    Topics: Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Treatment Outcome

2019
Ertugliflozin for the treatment of type 2 diabetes.
    Drugs of today (Barcelona, Spain : 1998), 2019, Volume: 55, Issue:3

    Topics: Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors

2019
Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?
    Journal of diabetes and its complications, 2020, Volume: 34, Issue:12

    Topics: Anti-Inflammatory Agents; Comorbidity; COVID-19; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Inflammation; Metformin; Pioglitazone; Risk Factors; SARS-CoV-2; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors

2020
Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Drug research, 2021, Volume: 71, Issue:9

    Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Obesity; Overweight; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Weight Loss

2021
Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 2; Exenatide; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Metformin; Network Meta-Analysis; Sitagliptin Phosphate

2022
Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis.
    Annals of medicine, 2023, Volume: 55, Issue:2

    Topics: Body Weight; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate

2023

Trials

165 trial(s) available for metformin and sitagliptin phosphate

ArticleYear
Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
    Current medical research and opinion, 2006, Volume: 22, Issue:10

    Topics: Adenosine Deaminase Inhibitors; Adult; Area Under Curve; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles

2006
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Diabetes care, 2006, Volume: 29, Issue:12

    Topics: Adenosine Deaminase Inhibitors; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Placebos; Proinsulin; Protease Inhibitors; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Triazoles

2006
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:2

    Topics: Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2007
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
    Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:2

    Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2007
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
    Diabetes care, 2007, Volume: 30, Issue:8

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Patient Selection; Placebos; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Triazoles

2007
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:5

    Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles

2007
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
    Current medical research and opinion, 2008, Volume: 24, Issue:2

    Topics: Adult; Aged; Area Under Curve; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2008
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:10

    Topics: Analysis of Variance; Biomarkers; Blood Glucose; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Triglycerides

2008
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
    Current medical research and opinion, 2009, Volume: 25, Issue:3

    Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Placebos; Pyrazines; Sitagliptin Phosphate; Triazoles

2009
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Metabolism: clinical and experimental, 2010, Volume: 59, Issue:6

    Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Resistin; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Tumor Necrosis Factor-alpha

2010
Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:3

    Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult

2010
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:2

    Topics: Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2010
The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.
    Diabetes care, 2010, Volume: 33, Issue:7

    Topics: Administration, Oral; Adult; Aged; Chemokine CXCL12; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Endothelial Cells; Enzyme Activation; Female; Hematopoietic Stem Cells; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pilot Projects; Pyrazines; Receptors, CXCR4; Sitagliptin Phosphate; Triazoles

2010
Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:4

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Metformin; Middle Aged; Peptide YY; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles

2010
[Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes].
    Revue medicale de Liege, 2010, Volume: 65, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Belgium; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Patient Satisfaction; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2010
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:5

    Topics: Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2010
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Lancet (London, England), 2010, Apr-24, Volume: 375, Issue:9724

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Failure; Treatment Outcome; Triazoles; Young Adult

2010
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.
    International journal of clinical practice, 2010, Volume: 64, Issue:5

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult

2010
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
    Lancet (London, England), 2010, Aug-07, Volume: 376, Issue:9739

    Topics: Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Computer-Assisted; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipid A; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms

2010
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
    Diabetes/metabolism research and reviews, 2010, Volume: 26, Issue:7

    Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2010
Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin.
    Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:10

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pilot Projects; Placebos; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2010
Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.
    Clinical drug investigation, 2010, Volume: 30, Issue:12

    Topics: Administration, Oral; Adult; Blood Glucose; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Tablets; Therapeutic Equivalency; Treatment Outcome; Triazoles; United States; Young Adult

2010
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:1

    Topics: Adolescent; Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult

2011
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:2

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles

2011
Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:3

    Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Detemir; Insulin, Long-Acting; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss

2011
Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:3

    Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Patient Satisfaction; Pyrazines; Quality of Life; Sitagliptin Phosphate; Surveys and Questionnaires; Treatment Outcome; Triazoles

2011
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
    International journal of clinical practice, 2011, Volume: 65, Issue:4

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss

2011
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:7

    Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult

2011
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:6

    Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms

2011
[Efficacy and tolerability of sitagliptin in type 2 diabetic patients inadequately controlled with metformin. A prospective observational study in austrian primary care].
    Wiener klinische Wochenschrift, 2011, Volume: 123, Issue:7-8

    Topics: Austria; Diabetes Mellitus, Type 2; Drug Tolerance; Female; Humans; Male; Metformin; Middle Aged; Prevalence; Primary Health Care; Prospective Studies; Pyrazines; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2011
Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.
    Diabetes research and clinical practice, 2011, Volume: 93, Issue:1

    Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Weight Gain

2011
A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:9

    Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult

2011
Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.
    International journal of clinical practice, 2011, Volume: 65, Issue:9

    Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult

2011
Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study.
    Clinical endocrinology, 2012, Volume: 77, Issue:2

    Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2012
Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:1

    Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2012
Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult

2012
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
    Diabetes care, 2012, Volume: 35, Issue:2

    Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms

2012
A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitaglipti
    Diabetic medicine : a journal of the British Diabetic Association, 2012, Volume: 29, Issue:11

    Topics: Adolescent; Adult; Aged; Argentina; Australia; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Germany; Glycated Hemoglobin; Greece; Humans; Hypoglycemia; Hypoglycemic Agents; India; Male; Metformin; Mexico; Middle Aged; Peptides; Pyrazines; Republic of Korea; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms

2012
The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients.
    Diabetes technology & therapeutics, 2012, Volume: 14, Issue:7

    Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Triazoles; Vascular Stiffness; Young Adult

2012
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
    Current medical research and opinion, 2012, Volume: 28, Issue:7

    Topics: Bacteriuria; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles; Urinary Tract Infections

2012
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
    Journal of diabetes, 2012, Volume: 4, Issue:3

    Topics: Abdominal Pain; Adult; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Diarrhea; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2012
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
    Diabetes research and clinical practice, 2012, Volume: 98, Issue:1

    Topics: Blood Glucose; C-Peptide; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Fasting; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Italy; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2012
Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.
    Lancet (London, England), 2012, Jun-16, Volume: 379, Issue:9833

    Topics: Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2012
Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.
    Diabetes care, 2012, Volume: 35, Issue:10

    Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Inflammation; Interleukin-18; Interleukin-6; Male; Metformin; Middle Aged; Nitriles; Oxidative Stress; Postprandial Period; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin

2012
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.
    Journal of diabetes, 2013, Volume: 5, Issue:1

    Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Triazoles

2013
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?
    Diabetes technology & therapeutics, 2012, Volume: 14, Issue:10

    Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrazines; Pyrrolidines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin

2012
Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    The Journal of the Association of Physicians of India, 2012, Volume: 60

    Topics: Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Triazoles

2012
Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
    Diabetes & metabolism, 2012, Volume: 38, Issue:4

    Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; France; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pilot Projects; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin; Young Adult

2012
Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.
    Diabetes care, 2012, Volume: 35, Issue:10

    Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Liraglutide; Metformin; Nausea; Patient Satisfaction; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2012
A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:17

    Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles

2012
Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:5

    Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles

2013
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:6

    Topics: Adolescent; Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrazines; Pyrimidines; Republic of Korea; Risk Reduction Behavior; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2013
A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy.
    Diabetic medicine : a journal of the British Diabetic Association, 2013, Volume: 30, Issue:7

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucose Clamp Technique; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles

2013
A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
    Diabetes technology & therapeutics, 2013, Volume: 15, Issue:3

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Obesity; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles

2013
Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
    Drug design, development and therapy, 2013, Volume: 7

    Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles

2013
Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus.
    Diabetes technology & therapeutics, 2013, Volume: 15, Issue:4

    Topics: Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles

2013
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
    Diabetes care, 2013, Volume: 36, Issue:9

    Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Triazoles

2013
Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study.
    Diabetes care, 2013, Volume: 36, Issue:9

    Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles

2013
Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical tri
    Diabetologia, 2013, Volume: 56, Issue:7

    Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; Young Adult

2013
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).
    Diabetes care, 2013, Volume: 36, Issue:8

    Topics: Adult; Blood Glucose; Comparative Effectiveness Research; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Outcome Assessment, Health Care; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles

2013
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
    Diabetologia, 2013, Volume: 56, Issue:12

    Topics: Adolescent; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles

2013
A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
    Diabetes technology & therapeutics, 2013, Volume: 15, Issue:10

    Topics: Adult; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Oxidative Stress; Patient Compliance; Prospective Studies; Pyrazines; Republic of Korea; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles

2013
Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:19

    Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycemic Index; Humans; Hypoglycemic Agents; Inflammation Mediators; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles

2013
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
    Diabetes care, 2014, Volume: 37, Issue:3

    Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Urinary Tract Infections; Weight Loss

2014
Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose.
    Diabetes, 2014, Volume: 63, Issue:2

    Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gene Expression Regulation; Glucose; Humans; Incretins; Insulin; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles

2014
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.
    Diabetes care, 2013, Volume: 36, Issue:12

    Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles

2013
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
    American heart journal, 2013, Volume: 166, Issue:6

    Topics: Aged; Aged, 80 and over; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Pyrazines; Research Design; Sitagliptin Phosphate; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles

2013
Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2013, Volume: 11, Issue:6

    Topics: Adult; Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Kidney Transplantation; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Gain; Weight Loss

2013
Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
    The American journal of managed care, 2014, Volume: 20, Issue:1 Suppl

    Topics: Aged; Blood Pressure; Body Mass Index; Canagliflozin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Quality Indicators, Health Care; Racial Groups; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles

2014
Both glimepiride and high-dose metformin are important for sustained glucose lowering in Japanese type 2 diabetes patients on glimepiride-sitagliptin-metformin therapy: subanalysis of a single-center, open-label, randomized study.
    Diabetes technology & therapeutics, 2014, Volume: 16, Issue:7

    Topics: Administration, Oral; Aged; Aged, 80 and over; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles

2014
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:5

    Topics: Blood Glucose; Blood Pressure; Canagliflozin; Candidiasis; Diabetes Mellitus, Type 2; Diuretics, Osmotic; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Thiophenes; Treatment Outcome; Triazoles; Weight Loss

2014
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes.
    Diabetologia, 2014, Volume: 57, Issue:5

    Topics: Adult; Aged; Blood Glucose; C-Peptide; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Insulin-Secreting Cells; Least-Squares Analysis; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiophenes; Time Factors; Triazoles

2014
The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes.
    Medical archives (Sarajevo, Bosnia and Herzegovina), 2013, Volume: 67, Issue:5

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Obesity; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Triglycerides

2013
Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women.
    Journal of bone and mineral metabolism, 2015, Volume: 33, Issue:2

    Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Amino Acids; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Lumbar Vertebrae; Metformin; Middle Aged; Osteocalcin; Osteogenesis; Osteoporosis, Postmenopausal; Postmenopause; Pyrazines; Sitagliptin Phosphate; Triazoles

2015
Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.
    Diabetes, 2014, Volume: 63, Issue:8

    Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Energy Intake; Gastric Inhibitory Polypeptide; Gastrointestinal Motility; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Incretins; Male; Metformin; Obesity; Pyrazines; Sitagliptin Phosphate; Triazoles

2014
Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
    PloS one, 2014, Volume: 9, Issue:4

    Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Mesylates; Metformin; Middle Aged; Oxadiazoles; Peptide YY; Prognosis; Pyrazines; Receptors, G-Protein-Coupled; Sitagliptin Phosphate; Triazoles

2014
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
    Diabetes care, 2014, Volume: 37, Issue:8

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Pyrazines; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2014
HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
    Diabetes care, 2014, Volume: 37, Issue:8

    Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles

2014
Metformin reduces circulating malondialdehyde-modified low-density lipoprotein in type 2 diabetes mellitus.
    Clinical and investigative medicine. Medecine clinique et experimentale, 2014, Aug-01, Volume: 37, Issue:4

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Male; Malondialdehyde; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles

2014
Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:1

    Topics: C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Up-Regulation

2015
[Effect of dipeptidyl peptidase-4 inhibitors on lipid metabolism in patients with type 2 diabetes mellitus].
    Terapevticheskii arkhiv, 2014, Volume: 86, Issue:8

    Topics: Blood Glucose; Body Mass Index; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Intra-Abdominal Fat; Lipid Metabolism; Lipids; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2014
Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
    Endocrine journal, 2015, Volume: 62, Issue:2

    Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Sitagliptin Phosphate

2015
Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study.
    PloS one, 2014, Volume: 9, Issue:11

    Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glutamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Plasma Volume; Sitagliptin Phosphate; Treatment Outcome

2014
The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
    Primary care diabetes, 2015, Volume: 9, Issue:5

    Topics: Aged; Asia; Australia; Biomarkers; Biphasic Insulins; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Aspart; Insulin, Isophane; Male; Metformin; Middle Aged; Sitagliptin Phosphate; South America; Time Factors; Treatment Outcome

2015
Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:5

    Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Proinsulin; Pyrimidines; Sitagliptin Phosphate

2015
Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:6

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Mycoses; Sitagliptin Phosphate; Sodium-Glucose Transport Proteins; Urinary Tract Infections

2015
Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes.
    Current medical research and opinion, 2015, Volume: 31, Issue:6

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Sitagliptin Phosphate

2015
Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:8

    Topics: Aged; Benzofurans; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucokinase; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrimidines; Sitagliptin Phosphate; Sulfonylurea Compounds

2015
Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:9

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Weight Loss

2015
Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.
    Advances in therapy, 2015, Volume: 32, Issue:5

    Topics: 1-Deoxynojirimycin; Adult; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Female; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sorbitol; Sulfonylurea Compounds; Thiazolidinediones; Triazoles

2015
A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
    Drug research, 2016, Volume: 66, Issue:2

    Topics: 1-Deoxynojirimycin; Adult; Benzhydryl Compounds; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Glucose; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Urine; Young Adult

2016
Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial.
    Trials, 2015, Aug-05, Volume: 16

    Topics: Biomarkers; Blood Glucose; Clinical Protocols; Feasibility Studies; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Metformin; Netherlands; Predictive Value of Tests; Research Design; Sitagliptin Phosphate; Stroke; Time Factors; Treatment Outcome

2015
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Latin America; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome

2016
A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.
    Journal of diabetes, 2016, Volume: 8, Issue:5

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Single-Blind Method; Sitagliptin Phosphate; Sulfonylurea Compounds; Time Factors; Treatment Outcome

2016
Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes.
    Medicine, 2016, Volume: 95, Issue:11

    Topics: Adult; Aged; Body Mass Index; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Obesity; Sitagliptin Phosphate; Treatment Outcome

2016
Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Asian People; Blood Glucose; Body Weight; China; Diabetes Mellitus, Type 2; Diarrhea; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Nausea; Sitagliptin Phosphate; Treatment Outcome; Young Adult

2016
Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:8

    Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Hypovolemia; Male; Metformin; Middle Aged; Mycoses; Reproductive Tract Infections; Sitagliptin Phosphate; Treatment Failure; Treatment Outcome; Urinary Tract Infections

2016
Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus.
    Journal of diabetes investigation, 2016, Volume: 7, Issue:5

    Topics: China; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome

2016
Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.
    Journal of diabetes, 2017, Volume: 9, Issue:4

    Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Infections; Male; Metformin; Middle Aged; Nausea; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome

2017
Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Piragliatin, a Glucokinase Activator, and Glyburide, a Sulfonylurea, in Type 2 Diabetic Patients.
    Clinical pharmacology in drug development, 2016, Volume: 5, Issue:6

    Topics: Adult; Aged; Benzeneacetamides; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Endpoint Determination; Enzyme Activators; Female; Glucokinase; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Sitagliptin Phosphate

2016
Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:11

    Topics: Adamantane; Aged; Combined Modality Therapy; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, Diabetic; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Down-Regulation; Drug Administration Schedule; Drug Therapy, Combination; Exercise Therapy; Feedback, Physiological; Female; Glucagon-Like Peptide 1; Humans; Male; Meals; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Vildagliptin

2016
Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Asia; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Substitution; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Nausea; North America; Sitagliptin Phosphate; Treatment Outcome

2016
Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
    Postgraduate medicine, 2016, Volume: 128, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Racial Groups; Sitagliptin Phosphate; Sulfonylurea Compounds; Weight Loss; Young Adult

2016
Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:12

    Topics: Aged; Bile Acids and Salts; Blood Glucose; Chenodeoxycholic Acid; Cholic Acid; Deoxycholic Acid; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Feces; Female; Gallbladder; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Organ Size; Postprandial Period; Sitagliptin Phosphate; Sulfonylurea Compounds; Ultrasonography; Ursodeoxycholic Acid

2016
Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
    Journal of diabetes, 2017, Volume: 9, Issue:7

    Topics: Aged; Asian People; Blood Glucose; Cardiovascular Diseases; China; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome

2017
Randomized Controlled Study of Metformin and Sitagliptin on Long-term Normoglycemia Remission in African American Patients With Hyperglycemic Crises.
    Diabetes care, 2016, Volume: 39, Issue:11

    Topics: Adolescent; Adult; Black or African American; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Longitudinal Studies; Male; Metformin; Middle Aged; Obesity; Prospective Studies; Single-Blind Method; Sitagliptin Phosphate; Young Adult

2016
Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.
    Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:1

    Topics: Age Factors; Aged; Blood Preservation; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Drug Therapy, Combination; Female; Fractures, Bone; Glycated Hemoglobin; Hip Fractures; Humans; Hypoglycemic Agents; Incidence; Insulin; Male; Metformin; Middle Aged; Osteoporotic Fractures; Proportional Hazards Models; Risk Factors; Sex Factors; Sitagliptin Phosphate; White People

2017
Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:2

    Topics: Adult; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome

2017
A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1).
    PloS one, 2016, Volume: 11, Issue:10

    Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Antioxidants; Biomarkers; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Drug Administration Schedule; Endothelium; Female; Glycated Hemoglobin; Hemodynamics; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Superoxide Dismutase; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult

2016
Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes.
    Journal of diabetes investigation, 2017, Volume: 8, Issue:3

    Topics: Asian People; China; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome

2017
Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study.
    Clinical pharmacology in drug development, 2016, Volume: 5, Issue:6

    Topics: Adult; Aged; Benzofurans; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Endpoint Determination; Enzyme Activators; Female; Glucokinase; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrimidines; Sitagliptin Phosphate

2016
A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.
    Current medical research and opinion, 2017, Volume: 33, Issue:4

    Topics: Acarbose; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome

2017
Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension.
    Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:5

    Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Piperazines; Republic of Korea; Sitagliptin Phosphate

2017
Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study).
    Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:6

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Young Adult

2017
Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.
    Vascular medicine (London, England), 2017, Volume: 22, Issue:3

    Topics: Adult; Aged; Biomarkers; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Female; Humans; Intercellular Adhesion Molecule-1; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Vasodilation; Wisconsin; Young Adult

2017
Beneficial effects of sitagliptin and metformin in non-diabetic hypertensive and dyslipidemic patients.
    Pakistan journal of pharmaceutical sciences, 2016, Volume: 29, Issue:6 Suppl

    Topics: Adult; Antihypertensive Agents; Biomarkers; Blood Pressure; Dipeptidyl-Peptidase IV Inhibitors; Dyslipidemias; Female; Humans; Hypertension; Hypolipidemic Agents; Lipids; Male; Metformin; Middle Aged; Pakistan; Prospective Studies; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Weight Loss

2016
Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
    Clinical therapeutics, 2017, Volume: 39, Issue:3

    Topics: Adult; Aged; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Sitagliptin Phosphate; Spleen; Thiazolidinediones; Tomography, X-Ray Computed

2017
Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
    Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:7

    Topics: Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug Therapy, Combination; Excipients; Exenatide; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incidence; Incretins; Injections, Jet; Male; Metformin; Middle Aged; Peptides; Sitagliptin Phosphate; Triglycerides; United States; Venoms

2017
Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
    Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:8

    Topics: Benzofurans; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Hemoglobins, Abnormal; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incidence; Incretins; Male; Metformin; Middle Aged; Receptors, G-Protein-Coupled; Sitagliptin Phosphate; Sulfones; United States

2017
Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
    Science China. Life sciences, 2017, Volume: 60, Issue:3

    Topics: Acarbose; Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome

2017
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:3

    Topics: Blood Pressure; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome

2018
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:5

    Topics: Aged; Body Mass Index; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Overweight; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors

2018
A 52-week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add-on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:6

    Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Sitagliptin Phosphate; Treatment Outcome

2018
SHORT-TERM SITAGLIPTIN-METFORMIN THERAPY IS MORE EFFECTIVE THAN METFORMIN OR PLACEBO IN PRIOR GESTATIONAL DIABETIC WOMEN WITH IMPAIRED GLUCOSE REGULATION.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2018, Volume: 24, Issue:4

    Topics: Adolescent; Adult; Body Mass Index; Diabetes, Gestational; Female; Glucose Intolerance; Humans; Metformin; Pilot Projects; Placebos; Pregnancy; Prospective Studies; Single-Blind Method; Sitagliptin Phosphate; Young Adult

2018
Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:8

    Topics: Aged; Aged, 80 and over; Aging; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucagon-Secreting Cells; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Meals; Metformin; Risk; Sitagliptin Phosphate; Sweden

2018
Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects.
    Clinical pharmacology in drug development, 2019, Volume: 8, Issue:3

    Topics: Adolescent; Adult; Bridged Bicyclo Compounds, Heterocyclic; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Glucuronosyltransferase; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds; UDP-Glucuronosyltransferase 1A9; Young Adult

2019
Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:10

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Metformin; Middle Aged; Republic of Korea; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Young Adult

2018
THE EFFICACY AND SAFETY OF CO-ADMINISTRATION OF SITAGLIPTIN WITH METFORMIN IN PATIENTS WITH TYPE 2 DIABETES AT HOSPITAL DISCHARGE.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2018, Volume: 24, Issue:6

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Male; Metformin; Middle Aged; Patient Discharge; Prospective Studies; Sitagliptin Phosphate

2018
Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Hepatology (Baltimore, Md.), 2019, Volume: 69, Issue:6

    Topics: Adult; Aged; Blood Glucose; Body Weight; Comorbidity; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Linear Models; Lipid Metabolism; Liraglutide; Male; Metformin; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Prognosis; Prospective Studies; Sitagliptin Phosphate; Treatment Outcome

2019
Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:3

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazoles; Republic of Korea; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidines; Treatment Failure

2019
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:4

    Topics: Aged; Deprescriptions; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Least-Squares Analysis; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome

2019
Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed-Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin.
    Clinical pharmacology in drug development, 2019, Volume: 8, Issue:5

    Topics: Adult; Bridged Bicyclo Compounds, Heterocyclic; Cross-Over Studies; Dietary Fats; Drug Combinations; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Young Adult

2019
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:4

    Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome

2019
Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea.
    Journal of endocrinological investigation, 2019, Volume: 42, Issue:7

    Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Prognosis; Sitagliptin Phosphate; Sulfonylurea Compounds

2019
Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:5

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Time Factors; Treatment Outcome

2019
Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
    JAMA, 2019, 04-16, Volume: 321, Issue:15

    Topics: Administration, Oral; Adult; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds

2019
Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:8

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Japan; Male; Metformin; Middle Aged; Prospective Studies; Single-Blind Method; Sitagliptin Phosphate; Thiophenes; Treatment Outcome

2019
Efficacy and safety of sitagliptin added to metformin and insulin compared with voglibose in patients with newly diagnosed type 2 diabetes.
    Clinics (Sao Paulo, Brazil), 2019, Volume: 74

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Prospective Studies; Sitagliptin Phosphate; Treatment Outcome

2019
A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:10

    Topics: Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrans; Sitagliptin Phosphate

2019
Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects.
    Clinical pharmacokinetics, 2020, Volume: 59, Issue:10

    Topics: Area Under Curve; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Sitagliptin Phosphate; Triazines

2020
Efficacy and safety of metformin and sitagliptin-based dual and triple therapy in elderly Chinese patients with type 2 diabetes: Subgroup analysis of STRATEGY study.
    Journal of diabetes investigation, 2020, Volume: 11, Issue:6

    Topics: Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Prognosis; Sitagliptin Phosphate

2020
Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks.
    Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:10

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Pyrimidines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome

2020
Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).
    Journal of diabetes investigation, 2021, Volume: 12, Issue:2

    Topics: Adult; Aged; Biomarkers; Blood Glucose; Bone and Bones; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Muscles; Prognosis; Prospective Studies; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult

2021
Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans.
    Nature communications, 2020, 07-28, Volume: 11, Issue:1

    Topics: Aged; Animals; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet, Atherogenic; Diet, High-Fat; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Female; Glucagon-Like Peptide-1 Receptor; Humans; Inflammation; Inflammation Mediators; Male; Metformin; Mice; Mice, Knockout; Middle Aged; Protein Isoforms; Sitagliptin Phosphate

2020
A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.
    Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:3

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome

2021
Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes.
    Diabetes & metabolism, 2021, Volume: 47, Issue:5

    Topics: Adult; Aged; Bile Acids and Salts; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gastrointestinal Microbiome; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Middle Aged; RNA, Ribosomal, 16S; Sitagliptin Phosphate; Sulfonylurea Compounds

2021
A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.
    Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:6

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Japan; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome

2021
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin.
    Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:9

    Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Japan; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome

2021
SITAgliptin for Depressive Symptoms in Type 2 Diabetes: A Feasibility Randomized Controlled Trial.
    Psychosomatic medicine, 2021, 10-01, Volume: 83, Issue:8

    Topics: Depression; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Feasibility Studies; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome

2021
Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance.
    BMJ open, 2021, 09-16, Volume: 11, Issue:9

    Topics: Blood Glucose; Brain Ischemia; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Feasibility Studies; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Ischemic Stroke; Metformin; Sitagliptin Phosphate; Stroke; Treatment Outcome

2021
Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial.
    Diabetes care, 2022, 01-01, Volume: 45, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Metformin; Sitagliptin Phosphate; Treatment Outcome

2022
A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes.
    Pediatric diabetes, 2022, Volume: 23, Issue:2

    Topics: Administration, Oral; Adolescent; Blood Glucose; Child; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Patient Safety; Sitagliptin Phosphate; Treatment Outcome

2022
Pharmacokinetics and Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Study.
    Drugs in R&D, 2022, Volume: 22, Issue:1

    Topics: Area Under Curve; China; Cross-Over Studies; Fasting; Healthy Volunteers; Humans; Metformin; Sitagliptin Phosphate; Tablets; Therapeutic Equivalency

2022
Analysis of pharmacoeconomic value of sitagliptin in the treatment of diabetes mellitus.
    European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Cost-Benefit Analysis; Diabetes Mellitus; Economics, Pharmaceutical; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds

2021
Sitagliptin/metformin improves the fertilization rate and embryo quality in polycystic ovary syndrome patients through increasing the expression of GDF9 and BMP15: A new alternative to metformin (a randomized trial).
    Journal of reproductive immunology, 2022, Volume: 150

    Topics: Bone Morphogenetic Protein 15; Female; Fertilization; Growth Differentiation Factor 9; Humans; Leptin; Metformin; Polycystic Ovary Syndrome; RNA, Messenger; Sitagliptin Phosphate

2022
Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Non-alcoholic Fatty Liver Disease; Prospective Studies; Sitagliptin Phosphate; Triglycerides

2022
Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
    The New England journal of medicine, 2022, 09-22, Volume: 387, Issue:12

    Topics: Blood Glucose; Comparative Effectiveness Research; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome

2022
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
    The New England journal of medicine, 2022, 09-22, Volume: 387, Issue:12

    Topics: Albuminuria; Blood Glucose; Cardiovascular Diseases; Comparative Effectiveness Research; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Drug Therapy, Combination; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heart Failure; Humans; Hypertension; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Microvessels; Sitagliptin Phosphate; Sulfonylurea Compounds

2022
Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study.
    Nature medicine, 2023, Volume: 29, Issue:2

    Topics: Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Patient Preference; Pioglitazone; Sitagliptin Phosphate; Treatment Outcome

2023
Anagliptin twice-daily regimen improves glycaemic variability in subjects with type 2 diabetes: A double-blind, randomized controlled trial.
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:5

    Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Protease Inhibitors; Sitagliptin Phosphate; Treatment Outcome

2023
Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study.
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:7

    Topics: Blood Glucose; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fatty Liver; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Treatment Outcome

2023
Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
    JAMA internal medicine, 2023, 07-01, Volume: 183, Issue:7

    Topics: Adult; Albuminuria; Diabetes Mellitus, Type 2; Disease Progression; Female; Glomerular Filtration Rate; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Kidney; Kidney Diseases; Liraglutide; Male; Metformin; Middle Aged; Sitagliptin Phosphate

2023
Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.
    Advances in therapy, 2023, Volume: 40, Issue:7

    Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Treatment Outcome

2023
Adding empagliflozin to sitagliptin plus metformin vs. adding sitagliptin to empagliflozin plus metformin as triple therapy in Egyptian patients with type 2 diabetes: a 12-week open trial.
    European review for medical and pharmacological sciences, 2023, Volume: 27, Issue:15

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Egypt; Glycated Hemoglobin; Humans; Metformin; Sitagliptin Phosphate

2023
Impact of Treviamet® & Treviamet XR® on quality of life besides glycemic control in type 2 DM patients.
    BMC endocrine disorders, 2023, Nov-08, Volume: 23, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Metformin; Prospective Studies; Quality of Life; Sitagliptin Phosphate

2023

Other Studies

152 other study(ies) available for metformin and sitagliptin phosphate

ArticleYear
Sitagliptin.
    Nature reviews. Drug discovery, 2007, Volume: 6, Issue:2

    Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles

2007
New treatments for diabetes.
    The New England journal of medicine, 2007, May-24, Volume: 356, Issue:21

    Topics: Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Combinations; Glycoproteins; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles; United States; United States Food and Drug Administration

2007
Sitagliptin/metformin (Janumet) for type 2 diabetes.
    The Medical letter on drugs and therapeutics, 2007, Jun-04, Volume: 49, Issue:1262

    Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2007
Janumet.
    JAAPA : official journal of the American Academy of Physician Assistants, 2007, Volume: 20, Issue:6

    Topics: Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles

2007
[New class of oral antidiabetic drugs. Effective in combination with metformin].
    MMW Fortschritte der Medizin, 2007, Volume: 149, Issue:1-2

    Topics: Administration, Oral; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms

2007
Treatment of type 2 diabetes mellitus and the incretin system.
    South Dakota medicine : the journal of the South Dakota State Medical Association, 2007, Volume: 60, Issue:5

    Topics: Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; United States; Venoms

2007
New medications help those with diabetes avoid heart trouble. Drugs mimic the body's natural insulin and glucose controls, but diet and exercise are still keys to controlling the disease.
    Heart advisor, 2007, Volume: 10, Issue:7

    Topics: Diabetes Mellitus; Diabetic Angiopathies; Exenatide; Heart Diseases; Humans; Hypoglycemic Agents; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms

2007
Type 2 diabetes: the end of clinical inertia.
    Southern medical journal, 2007, Volume: 100, Issue:8

    Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Nebulizers and Vaporizers; Peptides; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms

2007
Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
    Drugs of today (Barcelona, Spain : 1998), 2007, Volume: 43, Issue:10

    Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles

2007
Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
    Diabetes, obesity & metabolism, 2008, Volume: 10 Suppl 1

    Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Health Care Costs; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Biological; Models, Economic; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles

2008
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.
    Current medical research and opinion, 2009, Volume: 25, Issue:4

    Topics: Adolescent; Adult; Databases, Factual; Exenatide; Female; Glyburide; Humans; Hypoglycemic Agents; Insurance, Health; Male; Metformin; Middle Aged; Pancreatitis; Peptides; Pyrazines; Risk Assessment; Safety; Sitagliptin Phosphate; Triazoles; United States; Venoms; Young Adult

2009
Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin.
    Diabetes, 2009, Volume: 58, Issue:7

    Topics: Amyloid; Animals; Animals, Genetically Modified; Arginine; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose Clamp Technique; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Islet Amyloid Polypeptide; Islets of Langerhans; Metformin; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles

2009
By the way, doctor. I've had type 2 diabetes for 12 years; I'm now 81. I take metformin plus Januvia. My doctor has never suggested that I monitor myself on a daily basis with a meter. My hemoglobin A1c has been creeping up and is now at 7. Should I
    Harvard health letter, 2009, Volume: 34, Issue:7

    Topics: Aged, 80 and over; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles

2009
Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
    Prescrire international, 2009, Volume: 18, Issue:101

    Topics: Biguanides; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Combinations; Drug Synergism; Europe; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Sulfonylurea Compounds; Triazoles

2009
[Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].
    MMW Fortschritte der Medizin, 2009, May-07, Volume: 151, Issue:19

    Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucose; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Weight Loss

2009
[Type 2 diabetes: interview with Prof. Stephan Matthaei. Reaching HbA1c target value while preventing hypoglycemia].
    MMW Fortschritte der Medizin, 2009, Oct-15, Volume: 151, Issue:42

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Pyrazines; Reference Values; Sitagliptin Phosphate; Triazoles

2009
[Combination antidiabetic therapy. Better control of blood glucose values].
    MMW Fortschritte der Medizin, 2009, Oct-15, Volume: 151, Issue:42

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles

2009
Initial therapy for type 2 diabetes. Examination of a combination approach.
    Advance for nurse practitioners, 2009, Volume: 17, Issue:6

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Practice; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nurse Practitioners; Practice Guidelines as Topic; Primary Health Care; Pyrazines; Sitagliptin Phosphate; Triazoles

2009
Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion.
    Journal of diabetes science and technology, 2009, Volume: 3, Issue:1

    Topics: Body Weight; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Metformin; Models, Theoretical; Pyrazines; Sitagliptin Phosphate; Triazoles

2009
Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
    Diabetes, 2010, Volume: 59, Issue:4

    Topics: Animals; Cardiovascular System; Coronary Vessels; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Gene Deletion; Heart; Hypoglycemic Agents; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Ischemia; Pyrazines; Reference Values; Reperfusion; Sitagliptin Phosphate; Survivors; Triazoles

2010
New therapeutic options: management strategies to optimize glycemic control.
    The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:3 Suppl 2

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Life Style; Male; Metformin; Middle Aged; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms

2010
Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.
    Clinical science (London, England : 1979), 2010, Jun-08, Volume: 119, Issue:6

    Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Drug Therapy, Combination; Energy Intake; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metabolic Syndrome; Metformin; Mice; Mice, Inbred C57BL; Obesity; Pancreas; Pyrazines; Sitagliptin Phosphate; Telmisartan; Triazoles

2010
Individualised incretin-based treatment for type 2 diabetes.
    Lancet (London, England), 2010, Aug-07, Volume: 376, Issue:9739

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms

2010
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
    The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1

    Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms

2010
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
    The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1

    Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss

2010
Distinguishing among incretin-based therapies. Patient education and self-management.
    The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1

    Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms

2010
Distinguishing among incretin-based therapies. Introduction.
    The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1

    Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liraglutide; Metformin; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms

2010
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
    The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1

    Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms

2010
Sitagliptin attenuates metformin-mediated AMPK phosphorylation through inhibition of organic cation transporters.
    Xenobiotica; the fate of foreign compounds in biological systems, 2010, Volume: 40, Issue:12

    Topics: Adenylate Kinase; Animals; Biological Transport; Dogs; Hep G2 Cells; Humans; Kinetics; Metformin; Organic Cation Transporter 1; Phosphorylation; Pyrazines; Sitagliptin Phosphate; Triazoles

2010
Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats.
    Diabetes research and clinical practice, 2011, Volume: 92, Issue:2

    Topics: Animals; Caspase 3; ets-Domain Protein Elk-1; Fluorescent Antibody Technique; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hypoglycemic Agents; Insulin-Secreting Cells; Islets of Langerhans; Male; Metformin; Oligonucleotide Array Sequence Analysis; Pyrazines; Rats; Rats, Zucker; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles

2011
Simultaneous quantitation of metformin and sitagliptin from mouse and human dried blood spots using laser diode thermal desorption tandem mass spectrometry.
    Journal of pharmaceutical and biomedical analysis, 2011, Jun-01, Volume: 55, Issue:3

    Topics: Animals; Blood Stains; Calibration; Chromatography, High Pressure Liquid; Drug Stability; Drug Storage; Humans; Hypoglycemic Agents; Lasers, Semiconductor; Metformin; Mice; Mice, Inbred C57BL; Molecular Structure; Pyrazines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sitagliptin Phosphate; Species Specificity; Specimen Handling; Tandem Mass Spectrometry; Temperature; Triazoles

2011
Liquid chromatographic determination of sitagliptin either alone or in ternary mixture with metformin and sitagliptin degradation product.
    Talanta, 2011, Jul-15, Volume: 85, Issue:1

    Topics: Chromatography, Liquid; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Indicators and Reagents; Metformin; Pharmaceutical Preparations; Pyrazines; Quality Control; Reproducibility of Results; Sitagliptin Phosphate; Triazoles

2011
Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.
    Diabetic medicine : a journal of the British Diabetic Association, 2012, Volume: 29, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; United Kingdom; Young Adult

2012
The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes.
    Diabetes research and clinical practice, 2012, Volume: 95, Issue:1

    Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2012
Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.
    Translational research : the journal of laboratory and clinical medicine, 2012, Volume: 159, Issue:1

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Time Factors; Triazoles

2012
Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:7

    Topics: Animals; Apolipoprotein B-100; Biological Transport; Biomarkers; Blood Glucose; Cholesterol; Cholesterol Ester Transfer Proteins; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Intestinal Absorption; Lipoproteins, HDL; Macrophages; Male; Metformin; Mice; Mice, Obese; Mice, Transgenic; Pyrazines; Sitagliptin Phosphate; Triazoles

2012
Choosing a blood-glucose-lowering agent after metformin.
    Lancet (London, England), 2012, Jun-16, Volume: 379, Issue:9833

    Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles

2012
Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.
    Current medical research and opinion, 2012, Volume: 28, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Calibration; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Time Factors; Triazoles

2012
Association between sitagliptin adherence and self-monitoring of blood glucose.
    Journal of diabetes science and technology, 2012, May-01, Volume: 6, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Blood Glucose Self-Monitoring; Child; Computer Simulation; Diabetes Mellitus; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Logistic Models; Male; Medication Adherence; Metformin; Middle Aged; Odds Ratio; Predictive Value of Tests; Pyrazines; Risk Factors; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; United States; Young Adult

2012
Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system.
    Molecular pharmaceutics, 2012, Aug-06, Volume: 9, Issue:8

    Topics: Acetates; Anthraquinones; Azithromycin; Benzhydryl Compounds; Cinacalcet; Cloxacillin; Cresols; Cyclopropanes; Female; Fluorobenzenes; Humans; Hydrochlorothiazide; Losartan; Male; Metformin; Naphthalenes; Phenylpropanolamine; Piroxicam; Pyrazines; Pyrimidines; Quinolines; Rosuvastatin Calcium; Saliva; Sitagliptin Phosphate; Sulfides; Sulfonamides; Tamsulosin; Tolterodine Tartrate; Triazoles

2012
Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
    Journal of medical economics, 2012, Volume: 15 Suppl 2

    Topics: Computer Simulation; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Markov Chains; Metformin; Outcome Assessment, Health Care; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2012
Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS).
    Cardiovascular diabetology, 2013, Mar-28, Volume: 12

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Length of Stay; Logistic Models; Male; Metformin; Middle Aged; Multivariate Analysis; Pyrazines; Retrospective Studies; Secondary Prevention; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2013
Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
    Journal of managed care pharmacy : JMCP, 2013, Volume: 19, Issue:3

    Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Substitution; Glucagon-Like Peptide 1; Glycemic Index; Health Care Costs; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Failure; Triazoles; United States

2013
[Diabetes treatment in patients with chronic kidney disease].
    Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:21

    Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Substitution; Drug Therapy, Combination; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney Failure, Chronic; Kidney Function Tests; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles

2013
Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients.
    Diabetes care, 2013, Volume: 36, Issue:10

    Topics: Aged; Cognition Disorders; Diabetes Mellitus, Type 2; Endarterectomy, Carotid; Glyburide; Humans; Hypoglycemic Agents; Inflammation; Logistic Models; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles

2013
One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
    American journal of physiology. Endocrinology and metabolism, 2013, Aug-15, Volume: 305, Issue:4

    Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Hemizygote; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Male; Metformin; Mice; Mice, Transgenic; Pancreas; Pancreatic Neoplasms; Pancreatitis; Plaque, Amyloid; Pyrazines; Random Allocation; Recombinant Proteins; Sitagliptin Phosphate; Time Factors; Triazoles

2013
Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
    Journal of diabetes, 2014, Volume: 6, Issue:2

    Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Fasting; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Metformin; Middle Aged; Peptides; Piperidines; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Failure; Triazoles; Venoms

2014
Sitagliptin: results from clinical practice.
    Current medical research and opinion, 2013, Volume: 29, Issue:11

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles

2013
All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:3

    Topics: Denmark; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Stroke; Treatment Outcome; Triazoles

2014
[Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation].
    Revue medicale de Liege, 2013, Volume: 68, Issue:10

    Topics: Belgium; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Renal Insufficiency; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Triazoles

2013
Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Animals; Apoptosis; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Drug Evaluation, Preclinical; Fibroblasts; Fibronectins; Fibrosis; Glucagon-Like Peptide 1; Glucose Intolerance; Hypoglycemic Agents; Insulin; Male; Metformin; Myocardium; Myocytes, Cardiac; PPAR delta; Protein Isoforms; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles

2013
Combining sitagliptin/metformin with a functional fiber delays diabetes progression in Zucker rats.
    The Journal of endocrinology, 2014, Volume: 220, Issue:3

    Topics: Alginates; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Drug Combinations; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Polysaccharides, Bacterial; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Triazoles

2014
Characterization of the exocrine pancreas in the male Zucker diabetic fatty rat model of type 2 diabetes mellitus following 3 months of treatment with sitagliptin.
    Endocrinology, 2014, Volume: 155, Issue:3

    Topics: Administration, Oral; Animals; Blood Glucose; Body Weight; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Keratins; Ki-67 Antigen; Male; Metformin; Pancreas, Exocrine; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Triazoles

2014
Use of antidiabetic drugs in the U.S., 2003-2012.
    Diabetes care, 2014, Volume: 37, Issue:5

    Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Prescriptions; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Marketing of Health Services; Metformin; Pharmacies; Prescription Drugs; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; United States

2014
Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
    Journal of medical economics, 2014, Volume: 17, Issue:9

    Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Health Services; Humans; Hypoglycemic Agents; Life Expectancy; Liraglutide; Male; Metformin; Middle Aged; Models, Economic; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Smoking; Sulfonylurea Compounds; Sweden; Triazoles

2014
Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2014, Volume: 24, Issue:12

    Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Monitoring, Physiologic; Nitriles; Peptides; Pyrazines; Pyrrolidines; Registries; Sex Factors; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin

2014
Metformin, but not sitagliptin, enhances WP 631-induced apoptotic HepG2 cell death.
    Toxicology in vitro : an international journal published in association with BIBRA, 2015, Volume: 29, Issue:5

    Topics: Apoptosis; Daunorubicin; Hep G2 Cells; Humans; Hypoglycemic Agents; Metformin; NF-kappa B; Sitagliptin Phosphate; Tumor Suppressor Protein p53

2015
Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:10

    Topics: Aged; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Prescriptions; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Propensity Score; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Time Factors

2015
Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study.
    Diabetes & metabolism, 2015, Volume: 41, Issue:3

    Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Longitudinal Studies; Male; Metformin; Middle Aged; Prospective Studies; Sitagliptin Phosphate; Treatment Outcome

2015
A comparative study of smart spectrophotometric methods for simultaneous determination of sitagliptin phosphate and metformin hydrochloride in their binary mixture.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2015, Volume: 149

    Topics: Drug Combinations; Hypoglycemic Agents; Limit of Detection; Metformin; Sitagliptin Phosphate; Spectrophotometry; Tablets

2015
Development and Validation of a Method for Simultaneous Estimation of Metformin and Sitagliptin in Human Plasma by LC-MS-MS and Its Application in a Bioequivalence Study.
    Journal of chromatographic science, 2015, Volume: 53, Issue:9

    Topics: Chromatography, Liquid; Drug Stability; Humans; Metformin; Reproducibility of Results; Sensitivity and Specificity; Sitagliptin Phosphate; Tandem Mass Spectrometry; Therapeutic Equivalency

2015
Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Hemoglobin A; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate

2015
Description of anti-diabetic drug utilization pre- and post-formulary restriction of sitagliptin: findings from a national health plan.
    Current medical research and opinion, 2015, Volume: 31, Issue:8

    Topics: Adult; Aged; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Drug Utilization; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; National Health Programs; Sitagliptin Phosphate

2015
Analysis of metformin, sitagliptin and creatinine in human dried blood spots.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2015, Aug-01, Volume: 997

    Topics: Creatinine; Diabetes Mellitus; Dried Blood Spot Testing; Drug Stability; Humans; Hypoglycemic Agents; Linear Models; Metformin; Reproducibility of Results; Sensitivity and Specificity; Sitagliptin Phosphate

2015
Developing imprinted polymer nanoparticles for the selective separation of antidiabetic drugs.
    Journal of separation science, 2015, Volume: 38, Issue:19

    Topics: Biomimetic Materials; Humans; Hydrogen-Ion Concentration; Hypoglycemic Agents; Metformin; Microscopy, Atomic Force; Molecular Imprinting; Nanoparticles; Polymerization; Polymers; Sitagliptin Phosphate; Spectroscopy, Fourier Transform Infrared; Surface Properties

2015
[Effective prevention of coronary heart disease by early diabetes therapy].
    MMW Fortschritte der Medizin, 2015, Jul-23, Volume: 157, Issue:13

    Topics: Coronary Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Early Medical Intervention; Glycated Hemoglobin; Humans; Metformin; Sitagliptin Phosphate

2015
Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy.
    Pharmacological research, 2015, Volume: 100

    Topics: Adolescent; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Sitagliptin Phosphate; Thiazolidinediones

2015
Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study.
    Endocrine, 2016, Volume: 51, Issue:3

    Topics: Adipose Tissue; Adiposity; Adolescent; Adult; Aged; Body Composition; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Electric Impedance; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Obesity; Pericardium; Pilot Projects; Sitagliptin Phosphate; Young Adult

2016
Liraglutide vs. sitagliptin add-on to metformin treatment for type 2 diabetes mellitus: Short-term cost-per-controlled patient in Italy.
    Primary care diabetes, 2016, Volume: 10, Issue:3

    Topics: Biomarkers; Blood Glucose; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Costs; Drug Substitution; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Liraglutide; Meta-Analysis as Topic; Metformin; Models, Economic; National Health Programs; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Treatment Outcome

2016
[Impact of sitagliptin on aspirin resistance in patients with Type 2 diabetes mellitus].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2015, Volume: 40, Issue:11

    Topics: Aspirin; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Resistance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Oxidative Stress; Sitagliptin Phosphate

2015
Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2016, Volume: 63, Issue:5

    Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Lipids; Liraglutide; Liver Function Tests; Male; Metabolic Syndrome; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Peptides; Pilot Projects; Pioglitazone; Prospective Studies; Sitagliptin Phosphate; Thiazolidinediones; Venoms; Waist Circumference

2016
Drug Combo Adds No Benefit in Patients with Type 2 Diabetes.
    American family physician, 2016, Mar-15, Volume: 93, Issue:6

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Sitagliptin Phosphate

2016
Effects of Epothilone A in Combination with the Antidiabetic Drugs Metformin and Sitagliptin in HepG2 Human Hepatocellular Cancer Cells: Role of Transcriptional Factors NF-κB and p53.
    Asian Pacific journal of cancer prevention : APJCP, 2016, Volume: 17, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Benzoxazoles; Carcinoma, Hepatocellular; Dactinomycin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Epothilones; Hep G2 Cells; Humans; Hypoglycemic Agents; Liver Neoplasms; Metformin; NF-kappa B; Sitagliptin Phosphate; Tumor Suppressor Protein p53

2016
[One year persistence of metformin monotherapy versus metformin/sitagliptin fixed dose combination].
    Orvosi hetilap, 2016, Apr-17, Volume: 157, Issue:16

    Topics: Adult; Aged; Blood Glucose; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Combinations; Female; Humans; Hungary; Hypoglycemic Agents; Linear Models; Male; Medication Adherence; Metformin; Middle Aged; Retrospective Studies; Sitagliptin Phosphate; Treatment Outcome

2016
Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada.
    Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique, 2016, Volume: 23, Issue:2

    Topics: Aged; Blood Glucose; Canada; Canagliflozin; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Econometric; Quality-Adjusted Life Years; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds

2016
LC-tandem mass spectrometry method for the simultaneous determination of metformin and sitagliptin in human plasma after ion-pair solid phase extraction.
    Journal of pharmaceutical and biomedical analysis, 2016, Nov-30, Volume: 131

    Topics: Chromatography, Liquid; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Solid Phase Extraction; Therapeutic Equivalency

2016
Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add-ons to metformin: A retrospective cohort database study.
    Journal of diabetes, 2017, Volume: 9, Issue:7

    Topics: Aged; Blood Glucose; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Logistic Models; Male; Medication Adherence; Metformin; Middle Aged; Propensity Score; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Withholding Treatment

2017
Loss of Eyebrows and Eyelashes During Concomitant Treatment with Sitagliptin and Metformin.
    Current drug safety, 2017, Volume: 12, Issue:1

    Topics: Aged; Alopecia; Diabetes Mellitus, Type 2; Eyebrows; Eyelashes; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Treatment Outcome

2017
Diabetes prescribing rises by a third over five years.
    BMJ (Clinical research ed.), 2016, Oct-10, Volume: 355

    Topics: Diabetes Mellitus, Type 2; Drug Prescriptions; England; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate

2016
Management of Sitagliptin and Metformin Combination Toxic Overdose.
    The Journal of the Association of Physicians of India, 2016, Volume: 64, Issue:11

    Topics: Acidosis, Lactic; Adult; Drug Overdose; Female; Humans; Metformin; Sitagliptin Phosphate; Suicide, Attempted

2016
C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy.
    Journal of diabetes research, 2016, Volume: 2016

    Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prognosis; Retrospective Studies; Sitagliptin Phosphate; Treatment Outcome; Weight Loss

2016
Metformin-Induced Generalized Fixed Drug Eruption With Cutaneous Hemophagocytosis.
    The American Journal of dermatopathology, 2017, Volume: 39, Issue:6

    Topics: Aged, 80 and over; Biopsy; Diabetes Mellitus, Type 2; Drug Eruptions; Drug Substitution; Histiocytes; Humans; Hypoglycemic Agents; Immunohistochemistry; Lymphocytes; Lymphohistiocytosis, Hemophagocytic; Lymphoid Enhancer-Binding Factor 1; Male; Metformin; Sitagliptin Phosphate; Skin; Treatment Outcome

2017
Potential involvement of JNK1 repression in the hepatic effect of sitagliptin and metformin in rats subjected to high fat diet and chronic mild distress.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 85

    Topics: Animals; Behavior, Animal; Biomarkers; Chronic Disease; Depression; Diet, High-Fat; Disease Models, Animal; Down-Regulation; Gene Expression Regulation, Enzymologic; Insulin Resistance; Liver; Male; Metformin; Mitogen-Activated Protein Kinase 8; Non-alcoholic Fatty Liver Disease; Rats, Wistar; Signal Transduction; Sitagliptin Phosphate; Stress, Psychological; Time Factors

2017
Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on m
    Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:3

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heterocyclic Compounds, 2-Ring; Humans; Hypoglycemic Agents; Least-Squares Analysis; Male; Metformin; Middle Aged; Pyrans; Sitagliptin Phosphate; Treatment Outcome

2017
Learning Effective Treatment Pathways for Type-2 Diabetes from a clinical data warehouse.
    AMIA ... Annual Symposium proceedings. AMIA Symposium, 2016, Volume: 2016

    Topics: Adult; Aged; Consolidation Chemotherapy; Critical Pathways; Diabetes Mellitus, Type 2; Electronic Health Records; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Machine Learning; Male; Metformin; Middle Aged; Proportional Hazards Models; Sitagliptin Phosphate

2016
Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
    Diabetes care, 2017, Volume: 40, Issue:5

    Topics: Acute Disease; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin Glargine; Male; Metformin; Middle Aged; Pancreatitis; Peptides; Recombinant Fusion Proteins; Sitagliptin Phosphate; Venoms

2017
Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly.
    The Journal of clinical endocrinology and metabolism, 2017, 05-01, Volume: 102, Issue:5

    Topics: Adenoma; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Fatty Acids, Nonesterified; Gliclazide; Glucagon; Glucosides; Growth Hormone-Secreting Pituitary Adenoma; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Metformin; Middle Aged; Severity of Illness Index; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors

2017
Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients.
    Mediators of inflammation, 2017, Volume: 2017

    Topics: Adult; Atherosclerosis; Blood Glucose; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Interleukin-6; Lipid Metabolism; Male; Metformin; Middle Aged; Pioglitazone; Sitagliptin Phosphate; Thiazolidinediones

2017
A Versatile Liquid Chromatographic Method for the Simultaneous Determination of Metformin, Sitagliptin, Simvastatin, and Ezetimibe in Different Dosage Forms.
    Journal of AOAC International, 2018, Mar-01, Volume: 101, Issue:2

    Topics: Chromatography, High Pressure Liquid; Dosage Forms; Ezetimibe; Limit of Detection; Metformin; Simvastatin; Sitagliptin Phosphate

2018
Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients.
    European journal of clinical investigation, 2017, Volume: 47, Issue:11

    Topics: Adamantane; Adipose Tissue; Adult; Aged; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Vildagliptin

2017
The effect of sitagliptin on obese patients with insulin treatment-induced diabetes mellitus.
    European review for medical and pharmacological sciences, 2017, Volume: 21, Issue:15

    Topics: Adiponectin; Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Insulin Resistance; Leptin; Male; Metformin; Middle Aged; Nicotinamide Phosphoribosyltransferase; Obesity; Sitagliptin Phosphate; Triglycerides

2017
Recovery from Diabetic Macular Edema in a Diabetic Patient After Minimal Dose of a Sodium Glucose Co-Transporter 2 Inhibitor.
    The American journal of case reports, 2018, Apr-19, Volume: 19

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Macular Edema; Metformin; Middle Aged; Sitagliptin Phosphate

2018
An Evidence Based Study on Comparison of Adverse Drug Reactions of Metformin & Sitagliptin with their Combination.
    Indian journal of physiology and pharmacology, 2016, Volume: 60, Issue:2

    Topics: Diabetes Mellitus, Type 2; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Humans; Metformin; Sitagliptin Phosphate

2016
Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.
    Diabetes & metabolism, 2018, Volume: 44, Issue:4

    Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Retrospective Studies; Sitagliptin Phosphate

2018
SHORT-TERM SITAGLIPTIN-METFORMIN THERAPY IS MORE EFFECTIVE THAN METFORMIN OR PLACEBO IN PRIOR GESTATIONAL DIABETIC WOMEN WITH IMPAIRED GLUCOSE REGULATION.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2018, Volume: 24, Issue:7

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Treatment Outcome

2018
Metformin, sitagliptin, and liraglutide modulate serum retinol-binding protein-4 level and adipocytokine production in type 2 diabetes mellitus rat model.
    Canadian journal of physiology and pharmacology, 2018, Volume: 96, Issue:12

    Topics: Adipokines; Animals; Blood Glucose; Body Mass Index; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin Resistance; Lipids; Liraglutide; Male; Metformin; Rats; Rats, Wistar; Retinol-Binding Proteins; Sitagliptin Phosphate; Streptozocin

2018
Sitagliptin attenuates myocardial apoptosis via activating LKB-1/AMPK/Akt pathway and suppressing the activity of GSK-3β and p38α/MAPK in a rat model of diabetic cardiomyopathy.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 107

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Apoptosis; Biomarkers; Blood Glucose; Body Weight; Collagen; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Disease Models, Animal; Fatty Acids; Glucagon-Like Peptide 1; Glycogen Synthase Kinase 3 beta; Male; Metformin; Mitogen-Activated Protein Kinase 14; Myocardium; Organ Size; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Rats, Wistar; RNA, Messenger; Signal Transduction; Sitagliptin Phosphate

2018
Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:2

    Topics: Adult; Benzhydryl Compounds; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Health Care Costs; Health Resources; Humans; Insurance Claim Review; Male; Medicare Part D; Metformin; Middle Aged; Patient Acceptance of Health Care; Retrospective Studies; Sitagliptin Phosphate; United States

2019
THE CIRCLE OF CARE IN DIABETES: FROM HOME TO HOSPITAL TO HOME.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2018, Volume: 24, Issue:11

    Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Metformin; Patient Discharge; Sitagliptin Phosphate

2018
Side effects of frequently used oral antidiabetics on wound healing in vitro.
    Naunyn-Schmiedeberg's archives of pharmacology, 2019, Volume: 392, Issue:3

    Topics: Administration, Oral; Apoptosis; Carbamates; Caspases; Cell Line; Endopeptidases; Fibroblasts; Gelatinases; Glyburide; Humans; Hypoglycemic Agents; Keratinocytes; Membrane Proteins; Metformin; Piperidines; Receptors, CXCR4; Serine Endopeptidases; Sitagliptin Phosphate; Wound Healing

2019
Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:4

    Topics: Adult; Aged; Blood Glucose; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Costs; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin, Isophane; Male; Metformin; Middle Aged; Quality-Adjusted Life Years; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; United Kingdom

2019
Reply.
    Hepatology (Baltimore, Md.), 2019, Volume: 69, Issue:5

    Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate

2019
Letter to Editor: Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
    Hepatology (Baltimore, Md.), 2019, Volume: 69, Issue:5

    Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate

2019
The Future of the GLP-1 Receptor Agonists.
    JAMA, 2019, 04-16, Volume: 321, Issue:15

    Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Metformin; Sitagliptin Phosphate

2019
Pharmacokinetics of Metformin in Combination With Sitagliptin in Adult Horses After Enteral Administration.
    Journal of equine veterinary science, 2019, Volume: 72

    Topics: Animals; Horses; Hypoglycemic Agents; Incretins; Insulin; Metformin; Sitagliptin Phosphate

2019
Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes.
    Hepatology (Baltimore, Md.), 2019, Volume: 69, Issue:6

    Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Incretins; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate

2019
Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy.
    Journal of clinical pharmacology, 2019, Volume: 59, Issue:10

    Topics: Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones

2019
A HILIC-MS/MS assay for the quantification of metformin and sitagliptin in human plasma and urine: A tool for studying drug transporter perturbation.
    Journal of pharmaceutical and biomedical analysis, 2019, Oct-25, Volume: 175

    Topics: Biological Assay; Humans; Hydrophobic and Hydrophilic Interactions; Metformin; Plasma; Reproducibility of Results; Sitagliptin Phosphate; Tandem Mass Spectrometry

2019
Metformin and sitagliptin combination therapy ameliorates polycystic ovary syndrome with insulin resistance through upregulation of lncRNA H19.
    Cell cycle (Georgetown, Tex.), 2019, Volume: 18, Issue:19

    Topics: Animals; Apoptosis; Cells, Cultured; DNA (Cytosine-5-)-Methyltransferase 1; Drug Therapy, Combination; Female; Gonadal Steroid Hormones; Granulosa Cells; Insulin; Insulin Resistance; Luteinizing Hormone; Metformin; Phosphatidylinositol 3-Kinases; Phosphorylation; Polycystic Ovary Syndrome; Progesterone; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; RNA, Long Noncoding; Sitagliptin Phosphate

2019
In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin.
    Annals of internal medicine, 2019, 08-20, Volume: 171, Issue:4

    Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Metformin; Sitagliptin Phosphate

2019
Sitagliptin favorably modulates immune-relevant pathways in human beta cells.
    Pharmacological research, 2019, Volume: 148

    Topics: Cell Line; Diabetes Mellitus, Type 2; Gene Expression; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunologic Factors; Inflammation; Insulin-Secreting Cells; Interleukin-6; Liraglutide; Metformin; Signal Transduction; Sitagliptin Phosphate; Tumor Necrosis Factor-alpha; Up-Regulation

2019
Letter to the Editor: Intrahepatic Lipid Content After Insulin Glargine Addition to Metformin in Type II Diabetes Mellitus With Nonalcoholic Fatty Liver Disease.
    Hepatology (Baltimore, Md.), 2020, Volume: 71, Issue:3

    Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate

2020
Reply.
    Hepatology (Baltimore, Md.), 2020, Volume: 71, Issue:3

    Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate

2020
Costarting sitagliptin with metformin is associated with a lower likelihood of disease progression in newly treated people with type 2 diabetes: a cohort study.
    Diabetic medicine : a journal of the British Diabetic Association, 2020, Volume: 37, Issue:10

    Topics: Adult; Alberta; Cohort Studies; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Logistic Models; Male; Metformin; Middle Aged; Retrospective Studies; Sitagliptin Phosphate

2020
Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats.
    BMJ open diabetes research & care, 2019, Volume: 7, Issue:1

    Topics: Acarbose; Animals; Bacteria; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Feces; Gastrointestinal Microbiome; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Male; Metagenomics; Metformin; Rats; Rats, Zucker; RNA, Ribosomal, 16S; Sitagliptin Phosphate

2019
Metformin Hydrochloride and Sitagliptin Phosphate Fixed-Dose Combination Product Prepared Using Melt Granulation Continuous Processing Technology.
    AAPS PharmSciTech, 2019, Dec-12, Volume: 21, Issue:1

    Topics: Chemistry, Pharmaceutical; Drug Combinations; Humans; Metformin; Sitagliptin Phosphate; Transition Temperature

2019
Good long-term glycemic compensation is associated with better trabecular bone score in postmenopausal women with type 2 diabetes.
    Physiological research, 2019, 11-30, Volume: 68, Issue:Suppl 2

    Topics: Bone Density; Cancellous Bone; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Postmenopause; Sitagliptin Phosphate

2019
Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study.
    BMJ open diabetes research & care, 2020, Volume: 8, Issue:1

    Topics: Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Resistance; Male; Metformin; Middle Aged; Prognosis; Pyrimidines; Republic of Korea; Sitagliptin Phosphate; Thiazolidinediones

2020
Simultaneous ultra-trace quantitative colorimetric determination of antidiabetic drugs based on gold nanoparticles aggregation using multivariate calibration and neural network methods.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2020, Jun-15, Volume: 234

    Topics: Analysis of Variance; Calibration; Colorimetry; Gold; Hypoglycemic Agents; Least-Squares Analysis; Metal Nanoparticles; Metformin; Multivariate Analysis; Neural Networks, Computer; Reproducibility of Results; Sitagliptin Phosphate; Spectrophotometry, Ultraviolet

2020
Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients.
    Medical science monitor : international medical journal of experimental and clinical research, 2020, Apr-02, Volume: 26

    Topics: Benzhydryl Compounds; Blood Glucose; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome

2020
Effects of Metformin and Sitagliptin Monotherapy on Expression of Intestinal and Renal Sweet Taste Receptors and Glucose Transporters in a Rat Model of Type 2 Diabetes.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2020, Volume: 52, Issue:5

    Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Glucose Transport Proteins, Facilitative; Insulin Resistance; Intestine, Small; Kidney; Metformin; Rats, Zucker; Receptors, G-Protein-Coupled; RNA, Messenger; Signal Transduction; Sitagliptin Phosphate; Taste

2020
Comparing the effect of sitagliptin and metformin on the oocyte and embryo quality in classic PCOS patients undergoing ICSI.
    Irish journal of medical science, 2021, Volume: 190, Issue:2

    Topics: Adult; Female; Humans; Metformin; Oocytes; Polycystic Ovary Syndrome; Sitagliptin Phosphate; Sperm Injections, Intracytoplasmic

2021
Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes.
    Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:12

    Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Retrospective Studies; Sitagliptin Phosphate; Treatment Outcome

2020
Oral anti-diabetic drugs as endocrine disruptors in vitro - No evidence for additive effects in binary mixtures.
    Toxicology in vitro : an international journal published in association with BIBRA, 2021, Volume: 70

    Topics: Administration, Oral; Cell Line; Chromatography, Liquid; Drug Interactions; Endocrine Disruptors; Humans; Hypoglycemic Agents; Metformin; Simvastatin; Sitagliptin Phosphate; Steroids; Sulfonylurea Compounds; Tandem Mass Spectrometry

2021
Sitagliptin/Metformin: A New Medical Treatment in Polycystic Ovary Syndrome.
    Trends in endocrinology and metabolism: TEM, 2020, Volume: 31, Issue:12

    Topics: Female; Humans; Menstrual Cycle; Metformin; Ovulation; Polycystic Ovary Syndrome; Sitagliptin Phosphate

2020
Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin.
    PharmacoEconomics, 2021, Volume: 39, Issue:3

    Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate

2021
Pharmacoeconomic Analysis of Sitagliptin/Metformin for the Treatment of Type 2 Diabetes Mellitus: A Cost-Effectiveness Study.
    Value in health regional issues, 2021, Volume: 26

    Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Economics, Pharmaceutical; Ecuador; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate

2021
The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases.
    European journal of gastroenterology & hepatology, 2022, 01-01, Volume: 34, Issue:1

    Topics: Diabetes Mellitus, Type 2; Exenatide; Gliclazide; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Sitagliptin Phosphate

2022
Analysis of Metformin and Five Gliptins in Counterfeit Herbal Products: Designs of Experiment Screening and Optimization.
    Journal of AOAC International, 2021, Dec-11, Volume: 104, Issue:6

    Topics: Chromatography, High Pressure Liquid; Counterfeit Drugs; Dipeptidyl-Peptidase IV Inhibitors; Humans; Metformin; Sitagliptin Phosphate

2021
Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: Adamantane; China; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Humans; Linagliptin; Metformin; Middle Aged; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil; Vildagliptin

2021
Coadministration of sitagliptin or metformin has no major impact on the adverse metabolic outcomes induced by dexamethasone treatment in rats.
    Life sciences, 2021, Dec-01, Volume: 286

    Topics: Animals; Blood Glucose; Body Weight; Dexamethasone; Diabetes Mellitus, Experimental; Feeding Behavior; Glucose Tolerance Test; Hypoglycemic Agents; Male; Metformin; Rats; Rats, Wistar; Sitagliptin Phosphate

2021
Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes.
    Diabetes & metabolism, 2022, Volume: 48, Issue:3

    Topics: Cerebrovascular Disorders; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin

2022
Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin.
    Pediatric diabetes, 2022, Volume: 23, Issue:2

    Topics: Administration, Oral; Adolescent; Blood Glucose; Child; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Patient Safety; Sitagliptin Phosphate; Treatment Outcome

2022
Initial combination of metformin, sitagliptin, and empagliflozin in drug-naïve patients with type 2 diabetes: Safety and metabolic effects.
    Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:4

    Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Treatment Outcome

2022
Spectrophotometric Determination of Metformin in Different Pharmaceutical Combinations With Glipizide or Sitagliptin in Presence of Toxic Impurities of Metformin.
    Journal of AOAC International, 2022, Apr-27, Volume: 105, Issue:3

    Topics: Glipizide; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Tablets

2022
Validation of a rapid and economical RP-HPLC method for simultaneous determination of metformin hydrochloride and sitagliptin phosphate monohydrate: Greenness evaluation using AGREE score.
    Pakistan journal of pharmaceutical sciences, 2022, Volume: 35, Issue:1

    Topics: Chromatography, High Pressure Liquid; Green Chemistry Technology; Hypoglycemic Agents; Limit of Detection; Metformin; Reproducibility of Results; Sitagliptin Phosphate; Software

2022
Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
    Current medical science, 2022, Volume: 42, Issue:3

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Humans; Inflammation; Insulin Resistance; Liver Cirrhosis; Metabolic Syndrome; Metformin; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Sitagliptin Phosphate; Transaminases

2022
[Imeglimin: features of the mechanism of action and potential benefits].
    Problemy endokrinologii, 2022, 03-11, Volume: 68, Issue:3

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Metformin; Sitagliptin Phosphate; Triazines

2022
The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment.
    Journal of immunology research, 2022, Volume: 2022

    Topics: Acarbose; Animals; Hypoglycemic Agents; Immune Checkpoint Inhibitors; Insulin; Melanoma; Metformin; Mice; Pioglitazone; Sitagliptin Phosphate

2022
Emulating the GRADE trial using real world data: retrospective comparative effectiveness study.
    BMJ (Clinical research ed.), 2022, 10-03, Volume: 379

    Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome

2022
Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study.
    BMC endocrine disorders, 2022, Oct-13, Volume: 22, Issue:1

    Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Prospective Studies; Sitagliptin Phosphate; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters

2022
[In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve
    La Revue de medecine interne, 2023, Volume: 44, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycemic Control; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Treatment Outcome

2023
Development of extended-release metformin core tablet and synergistic coating of sitagliptin for the treatment of type-II diabetes mellitus - A comparative drug release evaluation with reference product.
    Pakistan journal of pharmaceutical sciences, 2022, Volume: 35, Issue:5

    Topics: Diabetes Mellitus, Type 2; Drug Liberation; Humans; Metformin; Polymers; Sitagliptin Phosphate; Tablets

2022
Metformin alone and in combination with sitagliptin induces depression and impairs quality of life in type 2 diabetes mellitus patients: An observational study.
    International journal of clinical pharmacology and therapeutics, 2023, Volume: 61, Issue:3

    Topics: Blood Glucose; Depression; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Quality of Life; Sitagliptin Phosphate

2023
In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin.
    Annals of internal medicine, 2023, Volume: 176, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Treatment Outcome

2023
A new application of isoindole fluorophore derivative in sitagliptin antidiabetic medication assay: Application to dosage forms and biological fluid evaluation.
    Luminescence : the journal of biological and chemical luminescence, 2023, Volume: 38, Issue:6

    Topics: Humans; Hypoglycemic Agents; Metformin; o-Phthalaldehyde; Sitagliptin Phosphate; Spectrometry, Fluorescence; Sulfhydryl Compounds

2023
In vitro validation of an in vivo phenotyping drug cocktail for major drug transporters in humans.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2023, Jul-01, Volume: 186

    Topics: Biological Transport; Drug Interactions; HEK293 Cells; Humans; Metformin; Organic Cation Transport Proteins; Organic Cation Transporter 2; Sitagliptin Phosphate

2023
Molecular insights of anti-diabetic compounds and its hyaluronic acid conjugates against aldose reductase enzyme through molecular modeling and simulations study-a novel treatment option for inflammatory diabetes.
    Journal of molecular modeling, 2023, Jul-08, Volume: 29, Issue:8

    Topics: Aldehyde Reductase; Diabetes Mellitus, Type 2; Humans; Hyaluronic Acid; Inflammation; Insulin Resistance; Ligands; Metformin; Molecular Docking Simulation; Molecular Dynamics Simulation; Phenformin; Sitagliptin Phosphate

2023
[Indicators of diabetes mellitus after liraglutide, sitagliptin/metformin, linagliptin, and sitagliptin].
    Revista medica del Instituto Mexicano del Seguro Social, 2023, Jul-31, Volume: 61, Issue:4

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Longitudinal Studies; Male; Metformin; Sitagliptin Phosphate; Treatment Outcome

2023
Comparison of therapeutic efficacy and safety of sitagliptin, dapagliflozin, or lobeglitazone adjunct therapy in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea and metformin: Third agent study.
    Diabetes research and clinical practice, 2023, Volume: 203

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome

2023
Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study.
    Clinical drug investigation, 2023, Volume: 43, Issue:12

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Drug Therapy, Combination; East Asian People; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Obesity; Sitagliptin Phosphate; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters; Treatment Outcome

2023
Comprehensive UHPLC-MS screening methods for the analysis of triazolopyrazine precursor and its genotoxic nitroso-derivative in sitagliptin pharmaceutical formulation.
    Journal of pharmaceutical and biomedical analysis, 2024, Jan-20, Volume: 238

    Topics: Chromatography, High Pressure Liquid; Drug Compounding; Metformin; Nitrosamines; Pharmaceutical Preparations; Pyrazines; Sitagliptin Phosphate

2024